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NEXT GENERATION ARYL HYDANTOINS AS ANTISCHISTOSOMAL AGENTS
Derek A. Leas, Ph. D.
University of Nebraska Medical Center, 2020
Advisor: Jonathan L. Vennerstrom, Ph. D.
Schistosomiasis, also known as “snail fever,” is both an acute and chronic disease spread
by trematode flukes from the tropical parasitic worm genus Schistosoma. The flukes are spread
via diseased freshwater snails, which release the parasites into the water column where they find a
new human host. According to the World Health Organization (WHO), 99 million people were
treated for schistosomiasis in 2017. The primary treatment used to combat schistosomiasis is the
drug praziquantel (PZQ), but due to high drug pressure and widespread administration, its
effectiveness has eroded because of rising drug resistance. Furthermore, PZQ is active against
adult but not juvenile schistosomes, a potential factor regarding the frequently observed failed
treatments.
In 1980, the orally active hydantoin Ro 13-3978 was identified as a compound with
antischistosomal activity. Although Ro 13-3978 is an effective inhibitor of schistosome growth,
its antiandrogenic side effects on the host were undesirable. Utilizing the Ro 13-3978 scaffold as
a starting point, we developed several libraries of structurally diverse analogs of Ro 13-3978.
While numerous compounds identified exhibited good antischistosomal activity and lower
antiandrogenic effects compared to Ro 13-3978, the desired potency was not achieved and a clear
correlation between good activity/low side effects and compound structural features was
indistinct. Building on this foundation, we reexamined the Ro 13-3978 SAR and designed a series
of compounds to strategically separate the desired antischistosomal properties of aryl hydantoins
from the undesirable antiandrogenic side effects.

iii
This research translated to the discovery of drug candidate 27 (AR102), which like Ro
13-3978, has high adult in vivo antischistosomal activity, but unlike Ro 13-3978, has substantial
juvenile in vivo antischistosomal activity and no androgen receptor activity. Drug candidate 27
also possesses superior pharmacokinetic properties compared to Ro 13-3978. After scale-up
synthesis, 27 is now progressing up the drug discovery ladder and we anticipate it will function as
a new potent schistosomiasis treatment with broad-spectrum activity against multiple schistosome
species and life stages.
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Chapter 1: Schistosomiasis overview
1.1 Introduction
Schistosomiasis is a tropical parasitic disease caused by infections with flukes of the
genus Schistosoma. The Centers for Disease Control and Prevention (CDC) characterizes
schistosomiasis as one of the most neglected diseases and in terms of impact and it is second only
to malaria as the most deadly parasitic disease. People from Sub-Saharan Africa, the Middle East,
Southeast Asia, and the Caribbean, comprised some of the 220.8 million people who required
preventive treatment for schistosomiasis in 2017 according to the World Health Organization
(WHO). There are six species of pathogenic schistosomes, namely Schistosoma intercalatum, S.
mekongi, S. guineensis, S. mansoni, S. japonicum, and S. haematobium (CDC). The former three
are confined geographically and the latter three have the largest geographical range and constitute
the majority of infections (CDC). At least 230 million people have been infected by schistosomes
and more than 300,000 deaths involving schistosomiasis are reported annually (Colley et al.,
2014; You et al., 2015). Apart from being an obvious health concern, often the disease is not of
major importance to many developed and underdeveloped countries and tends to be
overshadowed by other more recognized diseases. Effects such as climate change,
overpopulation, and high-traffic travel have also caused the cost of disease control to remain high
for many countries regarding the per capita health expenditure (Thétiot‐Laurent et al., 2013).
Onset symptoms (1–2 months) of the disease cause itchy skin followed by fever, chills,
coughing and muscles aches (CDC). Prolonged infections result in persistent chronic disorder in
endemic areas, resulting in anaemia, growth stunting, cognitive impairment, and decreased
aerobic capacity (Terer et al., 2013; Colley et al., 2014). Severe manifestations can lead to
obstructive uropathy, bladder calcification and cancer (S. haematobium), and periportal hepatic
fibrosis (S. mansoni and S. japonicum). Approximately 1.4 million disability–adjusted life years
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(DALYs) have been ascribed to schistosomiasis using the most recent DALY metrics (Murray et
al., 2018).
1.2 Schistosome life cycle
Schistosomes generally thrive in conditions containing poor hygiene and sanitation, often
reflecting the development of the region. The schistosome life cycle is very intricate involving
both commensalistic and parasitic relationships. The cycle begins when schistosome eggs present
in human feces come in contact with water and subsequently hatch to release miracidia larvae,
which then pursue the appropriate molluscan snail host. The miracidia transform into sporocysts
that then continue to multiply, while eventually maturing and via asexual reproduction producing
thousands of larvae called cercariae that then exit the snail host via excrement into the water
column thus infecting it. When the cercariae encounter a human host, they easily penetrate the
skin and migrate through the bloodstream towards the liver where they feed on blood and
continue to mature. The adult worms then migrate to the mesenteric veins where they pair off and
mate dioeciously, unlike other Digenea members that are all hermaphroditic (Popiel, 1986). The
female worms deposit eggs, which travel through blood vessels into the bladder or intestine, and
are then shed via urine or feces and the cycle repeats itself (Thétiot‐Laurent et al., 2013).
1.3 Prevention
A vaccine-like approach to controlling schistosomiasis, commonly designated “preventative
chemotherapy,” involves the administration of antischistosomal drugs, periodically to vulnerable
populations, to act as a “first response” mechanism to prevent further infections. While
preventative chemotherapy has resulted in significant antischistosomal reduction, it suffers from
high drug pressure resulting from widespread recurrent administration (Knopp et al., 2013).
Another argument for the development of similar treatment regimens is the fact that infections are
frequently unnoticed and parasite growth becomes significant before chemotherapy is
administered (Thétiot‐Laurent et al., 2013). High drug pressure can potentially lead to the
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emergence and hastening of drug resistance, causing once effective therapies to become
ineffective. Another more practical method to prevent the spread of schistosomiasis is merely
better education regarding water treatment and sanitary hygiene methods. While cleanliness
practices come across as the least challenging solutions for disease control, enforcement is an
undeniable issue, which is very region dependent, and therefore not a reliable preventative at this
point in endemic areas especially (Thétiot‐Laurent et al., 2013). Lastly, snail control has also been
explored as a prevention measure. The most commonly used molluscicide, niclosamide, has been
used to eradicate specific invertebrates and is effective in gastropod (snail) extermination.
Unfortunately, niclosamide is also toxic to many fish species, thus presenting a major negative
impact on wildlife and the aquaculture industry (Knopp et al., 2013).
1.4 Anthelminthic Therapy
1.4.1

Vaccines
The quest to develop a single-dose vaccine for the treatment and prevention of

schistosomiasis has been relatively fruitless. Numerous vaccine antigens have been explored and
the corresponding vaccine candidates gave less than 50 % immunity in mouse models, thus
vaccine advancement for schistosomiasis remains at a standstill. This phenomenon can be
rationalized because adult schistosomes can subsist up to thirty or more years in a human host,
implying they may employ sophisticated evasive reactions towards host immune responses
(Thétiot‐Laurent et al., 2013). Additionally the production and development of vaccines carries
its own complications such as high costs, high failure rates, sensitive time-consuming synthesis,
and the inability for demand to coincide with the ability to pay (Oyston et al. 2012). The vaccine
bilhvax was the most recent candidate submitted for clinical trials, but unfortunately failed during
phase III trials; thus a schistosomiasis vaccine currently remains non-existent (Thétiot‐Laurent et
al., 2013).
1.4.2. Abandoned drugs.
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1.4.2.1 Antimony drugs
During the early 20th century, various antimony salts were discovered to have activity
against S. mansoni, S. haematobium and S. japonicum, with the potassium tartrate salt being the
first antimony derivative to be routinely used (Christopherson et al., 1918; Thétiot‐Laurent et al.,
2013). The drugs function via inhibition of phosphofructokinase, which subsequently halts
glycolysis preventing schistosome replication and eventually leading to death. Although effective,
daily doses were required for a treatment period of a month or more, often adding up to a
considerable overall sum of 15–30 grams of drug required for treatment. Antimony drugs were
also eventually found to have high toxicity stemming from gastrointestinal, cardiovascular,
hepatic, and dermatological side effects, thus their use in antischistosomal therapy was
consequently terminated (Thétiot‐Laurent et al., 2013).
1.4.2.2 Organophosphorus compounds
In the mid-1950s several organophosphorus derivatives were found to possess
antihelminthic activity. Most notably, the phosphorus based insecticide metrifonate had marginal
activity (~50 % WBR) against S. mansoni, S. haematobium and S. japonicum in various mammal
models. When compared to the antimony-based drugs, it was found to have very little toxicity
and was very well tolerated, however it rarely completely eradicated the parasites and therefore
multiple treatments were often necessary (Campbell et al., 1966; Werbel et al., 1967). Eventually,
resistance to metrifonate manifested and the drug ultimately ceased to be recommended by the
WHO in 2000 and was withdrawn from the market.
1.4.2.3 Niridazole
Originally developed as an antibiotic, niridazoles’ activity relies on the thiazole with its
nitro group pharmacophore. Dosages of 25–40 mg kg-1 d-1 administered for seven days gave
worm burden reductions of 70–100 %. While effective, niridazole suffered from severe toxicity
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leading to neurological side effects, acute psychotic syndrome, and loss of consciousness. Other
side effects include digestive disorders and cardiovascular symptoms (Abdallah et al., 1969;
Coutinho et al., 1969).
1.4.2.4 Oltipraz
The 1,2‐dithiole‐3‐thione compound oltipraz was originally synthesized in the 1970s. It
was found to be active against S. haematobium, S. intercalatum, and S. mansoni. Oral doses of
20–35 mg kg-1 d-1, 1–3 times per day, led to 80–95 % WBR. Mild side effects range from nausea,
vomiting, aches and pain, headache, dizziness, and drowsiness. Severe side effects are caused by
paresthesias and acute pains at the fingertips, triggered by a phototoxic response observed in up to
30% of treated patients exposed to ultraviolet light (sunlight). Photo-onycholysis (separation of
the nail plate from the nail bed) was observed in some cases. These acute side effects led to the
withdrawal of the drug candidate from clinical trials in the mid-eighties (Cioli et al., 1995;
Thétiot‐Laurent et al., 2013).
1.4.3

Clinically used drugs

1.4.3.1 Oxamniquine
The p-aminotoluene derivative oxamniquine was first used to treat schistosomiasis in
South America during the early seventies (Jordan, 1985). Although effective, oxamniquine is
only effective against adult S. mansoni with a therapeutic oral doses of 40 mg kg-1 and up to 82%
cure rates (Knopp et al., 2013). Side effects associated with oxamniquine treatment comprise
abdominal pain, diarrhea, and fever (Jordan, 1985). It is also worth noting that some patients,
especially children, are not completely cured by the first treatment, often requiring periodic
followup treatments. While not commercially available in the United States, Brazil continues to
use oxamniquine, a consequence due to having the largest burden of S. mansoni in the new world.
Systematic treatment with oxamniquine also remains routinely in use for cases where
praziquantel (vide infra) failure or resistance occurs (Drugs.com, 2019; Sleigh et al., 1986).
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Lastly, the future use of oxamniquine remains uncertain due to potential drug resistance and its
high production costs (Doenhoff et al., 2002).
1.4.3.2 Praziquantel
As no vaccine exists to combat schistosomiasis, chemotherapy remains the most widely
used method for prevention and treatment. After more than forty years since its introduction, the
fundamental treatment still used to combat schistosomiasis is the drug praziquantel (PZQ). E.
Merck and Bayer AG (Merck and Bayer) began studying the anthelmintic activity of
pyrazinoisoquinoline derivatives in 1972, which subsequently led to the discovery and
development of PZQ in 1975 (Andrews et al., 1983). While very inexpensive (0.08 USD for a
child dose) and still relatively effective, PZQ is primarily potent against adult schistosomes, and
has little activity against other schistosoma species lifecycle stages (Hotez et al., 2010; Utzinger
et al., 2000). Furthermore, even if one successfully treats a schistosomiasis infection using PZQ,
the immature juvenile worms will eventually become egg-laying adults and may cause another
infection thus requiring follow-up curative assessment (Tchuenté et al., 2004).
1.4.3.2.1. PZQ structure activity, toxicity, metabolism, and excretion
PZQ is a colorless crystalline solid that has a bitter taste and is stable and relatively water
insoluble. Many structure activity relationship (SAR) studies have been conducted on the PZQ
core skeleton. While several derivatives have exhibited similar activity to PZQ, none thus far
identified is superior to the parent drug, suggesting its structure refinement may have reached its
apex; this further supports the necessary development of a new antischistosomal chemotype
(Andrews et al., 1983; Laurent et al., 2008; Liu et al., 2012).
Compared to current and former antischistosomal drugs, acute toxicity, chronic toxicity,
and carcinogenicity testing reveal PZQ exhibits very low toxic side effects in multiple species
such as bacteria, yeasts, insects, and several mammal models. Rats tolerated oral administration
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doses of up to 1000 mg/kg repeated daily for four weeks, and dogs up to 180 mg/kg for 13 weeks
without any organ mutagenicity. PZQ showed no reproductive or teratogenic effects in rats, mice
and rabbits. Uninfected and schistosome-infected humans gave no sign of a mutagenic damage
(Frohberg et al., 1984).
PZQ undergoes an extensive first-pass metabolism in the liver by the CYP system and
then is rapidly eliminated via the kidneys, of which 90% occurs within 24 hours. This metabolic
instability necessitates the need for multiple high-dose treatments, which can frequently lead to a
heavy burden on the infected patient and consequently leads to incomplete cures. In addition, as
previously mentioned, PZQ has little activity towards juvenile schistosomula, the young
developmental stage of the parasite (Olliaro et al., 2014; Bergquist et al., 2017).
1.4.3.2.2 Mechanism of action (MOA).
Attempts to understand PZQs MOA have so far been fruitless and therefore the site and
identity of molecular targets remain unknown. The primary effects of the drug in adult worms
consists of persistent muscular contraction and tegumental vacuolization, which subsequently
leads to exposure of parasite antigens on the worm surface. Secondary effects include
depolarization of the schistosome tegument, inhibition of glucose uptake, and decrease of
glycogen content. These combined responses are thought to be related to PZQ-dependent
disruption of Ca2+ homeostasis in worms, inferring interference with inorganic ion transport,
specifically the Cavβ ion channel subunit of the schistosome (Andrews et al., 1983; Aragon et al.,
2009; Greenberg et al., 2005).
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Figure 1.1. Antischistosomal Agents
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1.4.3.2.3 Drug resistance
After more than 40 years of high chemotherapeutic drug pressure, studies have revealed
evidence of drug resistant schistosomes. S. mansoni isolates collected from several individuals
from Kisumu, Kenya, were less susceptible to PZQ in contrast to samples collected from other
sources further suggesting natural selection for worms with less vulnerability is possible and is
rising (Melman et al., 2009). Reports of S. Mansoni resistance to PZQ have also come from Egypt
and Senegal (Doenhoff et al., 2002). It is also worth noting that it is possible to induce resistance
of S. mansoni and S. japonicum to PZQ in mice under laboratory conditions. In an early study, six
or seven drug-treated passages of S. mansoni in mice were completed for PZQ, with the amount
of drug administered to the infected mice being increased with each passage. Eighty percent of
the worms of the sixth passage selected for PZQ resistance survived three doses of 300 mg/kg of
PZQ given between days 28 and 37 after infection, and 93% of those of the seventh passage
survived the same dose. The results suggest that S. mansoni subjected to drug pressure can
develop resistance to PZQ over the course of relatively few passages (Fallon et al., 1994). If a
PZQ-resistant mutant did proliferate to plague-like proportions, there are few practical therapy
options available. Thus, even though there is a demand for novel treatment options, the pipeline is
meager due to schistosomiasis drug development being overshadowed by other more widely
known pathogenic microbes (Melman et al., 2009).
1.4.4

Ro 13-3978 as an antischistosomal prototype
In 1980, the orally active hydantoin Ro 13-3978 was identified by Hoffmann La-Roche,

as a compound with antischistosomal activity. Although active, further investigation into its
antischistosomal properties was terminated after the introduction of PZQ to the drug market.
(Bernauer et al., 1980; Cioli et al., 1995; Link et al., 1984; Dias et al., 1985). A potential catalyst
for Ro 13-3978 abandonment may have been linked to its undesirable antiandrogenic side effects
on the host, although not an unexpected outcome given that it’s a structurally close analogue to
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the androgen receptor (AR) antagonist nilutamide which contains a nitro group in place of the Ro
13-3978 fluorine atom. To put AR activity in perspective, nilutamide and Ro 13-3978 inhibit
dihydrotestosterone (DHT)-induced cell proliferation in the androgen–dependent LAPC4 prostate
cancer cell line (Jones and Diamond, 2008) with respective IC50 values of 0.52 and 11 μM. It is
also not surprising that nilutamide has some measureable antischistosomal activity, although
weak (Keiser et al., 2010). Being that schistosome species do not bear ARs, it’s therefore
plausible to strategically separate the desired antischistosomal properties of aryl hydantoins from
the undesirable antiandrogenic side effects through SAR studies (de Menonca et al., 2000).
Several characteristics of Ro 13-3978 support it as a compelling antischistosomal
prototype. First, Ro 13-3978 is easily synthesized using one-step procedures from either an
isocyanate starting material (Link and Stohler, 1984; Bernauer et al., 1980), or via Ullman
coupling or Chan Lam coupling reactions. Second, Ro 13-3978 has a good pharmacokinetic
profile with an elimination half-life greater than 40 h in experimental animals (unpublished data).
Third, Ro 13-3978 has high oral efficacy against all three major schistosome species—S.
mansoni, S. haematobium and S. japonicum—in a range of animal models (Link and Stohler,
1984). Validating the Roche data (Link and Stohler, 1984), we found that Ro 13–3978 had single
oral dose ED50 values of 15 and 140 mg/kg against adult and juvenile S. mansoni in a mouse
model (Keiser et al., 2015). In this same schistosome mouse model, PZQ is substantially less
potent against adult S. mansoni, with reported ED50 values ranging from 172 to 202 mg/kg, and it
has no significant activity against juvenile stages of the parasite (Link and Stohler, 1984; Keiser
et al., 2011). In contrast, we found that Ro 13-3978 has demonstrable activity against the juvenile
stage of the parasite; in S. mansoni-infected mice (juvenile worms), Ro 13-3978 had a single oral
dose ED50 of 140 mg/kg. Furthermore, Ro 13-3978 is schistosome specific as we observed that
this aryl hydantoin had no activity in mice infected with the intestinal fluke E. caproni or the liver
fluke F. hepatica. It is also important to note that in a preliminary in vivo acute toxicity
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experiment, Link and Stohler (1984) observed no apparent toxicity following administration of a
single 1250 mg/kg dose of Ro 13-3978 to mice. We also found that Ro 13-3978, at concentrations
up to 90 μM, was also not cytotoxic to rat skeletal myoblast L6 cells.
Interestingly, at concentrations up to 170 μM, Ro 13-3978 had virtually no effect on ex
vivo adult S. mansoni (Keiser et al., 2015). As Ro 13-3978 forms only one minor and inactive
Phase I metabolite, gem-dimethyl mono-hydroxyl derivative AR40, active metabolites do not
elucidate the unusual discrepancy between the in vitro and in vivo antischistosomal activity
(Keiser et al., 2015; Wang et al., 2016). Our preliminary studies suggest that the in vivo
antischistosomal potency of Ro 13-3978 may stem from a possible host-mediated immune
response.
To investigate differential immune cell activation resulting from Ro 13-3978 treatment,
immunohistological investigations were conducted using paraffinized vein and liver samples from
Ro 13-3978-treated S. mansoni-infected mice. At 24 h post-treatment, substantial macrophage
recruitment to the veins was observed, along with a modest increase in circulating B cells, and at
48 h, neutrophils and T cells were also present. However, in a parallel experiment, treatment with
PZQ showed even higher levels of cellular recruitment (Panic et al., 2017). Notably, Ro 13-3978
did not enhance phagocytosis with J774.2 macrophage cells. As worms isolated from Ro 13-3978-treated mice showed damage consistent with potent eosinophilic-induced damage (Glauert
et al., 1978; Keiser et al., 2015), we further investigated purified eosinophils obtained from
uninfected mice treated with either Ro 13-3978 or the inactive aryl hydantoin control AR59.
Unexpectedly, we found that eosinophils from mice exposed to Ro 13-3978, but not AR59, had
strongly heightened superoxide release, a hallmark of eosinophil activation consisting of vacuolar
degranulation. These data prompted our continued interest in further evaluating the potentially
unique mechanism of action of these aryl hydantoins.
1.4.5 Second-generation Ro 13-3978 derivatives
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Utilizing the Ro 13-3978 scaffold discovered by Hoffman La-Roche, Wang et al. (2016)
developed several libraries of structurally diverse analogs of Ro 13-3978. All of the synthesized
derivatives had calculated polar surface area (PSA), measured LogD7.4, aqueous kinetic solubility,
and estimated plasma protein binding values in ranges predictive of good absorption-distributionmetabolism-excretion (ADME) profiles. N3-Aryl hydantoins, hydantoin heterocycle variants, and
hydantoins substituted at the 5-position with methyl, hydrogen, and hydroxymethyl combinations,
had stable metabolic profiles. Three of the N3-substituted aryl hydantoins had high
antischistosomal activity and were less antiandrogenic than Ro 13-3978. While numerous
compounds identified exhibited decent antischistosomal activity, the desired activity and
antiandrogenic potency was not achieved and a clear correlation between good activity/low side
effects and compound structural features was indistinct.
1.4.6 Next-generation Ro 13-3978 derivatives as antischistosomal agents
In this dissertation, I built upon the investigations conducted by Roche (Link and Stohler,
1984) and Wang et al. (2016) to design a third-generation aryl hydantoin series in order to
identify analogs with superior antischistosomal efficacy, selectivity, and ADME profiles. To
accomplish this objective, we further optimized the promising antischistosomal aryl hydantoin
chemotype and explored numerous structural isosteres that were not previously synthesized or
tested. The underlying motivation for this research was to strategically separate the desired
antischistosomal properties of aryl hydantoins from the antiandrogenic undesirable side effects.
Using this rationale, we succeeded in discovering frontrunner drug candidate AR102 (27), which
possesses no antiandrogenic potency and high antischistosomal activity in both adult and juvenile
S. mansoni. We feel we have now completed optimization of this compound series and have
several backup compounds if necessary.
This dissertation will be outlined as follows:
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Chapter 2 discusses a new chemical reaction for the conversion of anilines to the
necessary aryl bromides and iodides needed for aryl hydantoin synthesis.



Chapter 3 discusses the optimization of Ro 13-3978 which led to the identification of
lead compounds 27 and 28 as potential single-dose aryl hydantoin drug development
candidates.



Chapter 4 provides an overall summary of this dissertation.
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Chapter 2: A New Chemical Reaction for the Conversion of Anilines to Aryl Bromides and
Iodides

Abstract
To access aryl halide starting materials required for the synthesis of various target aryl
hydantoins, we invented a new one-pot metal-free synthesis of aryl bromides and iodides from
anilines via halogen abstraction from bromotrichloromethane or diiodomethane (Leas et al.,
2017). This new reaction is a convenient alternative to the classic Sandmeyer reaction.
2.1 Introduction
Aryl halides are pivotal intermediates in palladium- and copper-catalyzed cross-coupling
reactions (Nicolaou et al., 2005). Haloarenes are also important structural motifs in bioactive
compounds (Cabrita et al., 2010; Wilken et al., 2013; Lu et al., 2012; Xu et al., 2014).
Ever since Sandmeyer reported that aryldiazonium halides undergo copper halide catalyzed
decomposition into haloarenes, multiple reaction variants have been developed such as in
situ diazotization (Cadogan et al., 1966), substitutive deamination (Doyle et al., 1977), phasetransfer catalysis (Bartsch et al., 1979; Korzeniowski et al., 1977), and nucleophilic substitution
(Lucas et al., 1943). Although these previous syntheses of aryl halides from aryl amines produce
satisfactory yields, they suffer from numerous competing reactions, time-consuming workup,
diazonium salt isolation, and excess halogenation (Doyle et al., 1977; Hodgson et al., 1933;
Karimi et al., 2014; Ku et al., 1981).
A potentially attractive alternative to conventional aryl halide syntheses is free-radicalmediated halogen abstraction. Halogen abstraction was proposed by Oae et al. (1979), in the
conversion of anilines, treated with tert-butyl thionitrate in the presence of bromoform and iodide,
to aryl bromides and iodides. Free-radical generation offers halogen abstraction in solution under
mild reaction conditions compatible with sensitive substrates. Recently Burglova et al. (2016)
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described a procedure for one-step deuterium introduction by deamination of anilines (Scheme
2.1). Using this as a springboard, we explored the conversion of anilines to the corresponding aryl
bromides and iodides. We now describe a convenient one-pot method for the metal-free synthesis
of aryl bromides and iodides from anilines by halogen abstraction from BrCCl3 and CH2I2 under
weakly acidic conditions.
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Scheme 2.1. Aromatic Deamination
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2.2 Results and Discussion
We began model reaction development by exploring the reaction of 4-aminobenzonitrile
(1a) (Table 2.1, entry 1) with NaNO2 and a large molar excess of BrCCl3 in the presence of
HOAc using a CH2Cl2/H2O two-phase solvent system for 24 h at rt. Under these conditions, 4bromobenzonitrile (2a) was generated in good yield (70%). Using 2 equiv of BrCCl3 and a
reaction time of 1 h (Table 2.1, entry 5), we found that aniline 1a was converted to aryl halide 2a
in 84% yield. Thus, excess halogen atom source had a small effect on product formation and was
optimal at 2 equiv with 5 equiv of NaNO2. Changing the acid source from HOAc to HCl (entry 8)
diminished the yield of product 2a slightly (75%).

23
Table 2.1. Optimization of the Reaction Conditions
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When CCl4 was used as the halogen source (entry 10), benzonitrile was formed,
suggesting hydrogen abstraction from CH2Cl2 is faster than chlorine abstraction. CBr4 and CH2I2
afforded the corresponding halide products 2a and 3a in moderate to good yields (Table 2.1,
entries 12 and 13). When we ran the reaction under Ar (Table 2.1, entry 14), the yield of 2a
increased only slightly (90% vs 84%). Increasing the reaction temperature from rt to 70 °C (Table
2.1, entry 15) eroded the yield (64%) due to generation of benzonitrile (7%), 4-nitrobenzonitrile
(5%), and 4,4-(1-triazene-1,3-diyl)bis-benzonitrile (21%). Although a single-phase CH3CN/H2O
system (Table 2.1, entry 9) gave a yield similar to that of the biphasic CH2Cl2/H2O system (Table
2.1, entry 5), the latter is preferred due to the solubilizing power of CH2Cl2, easy diazotization in
the water layer, and convenient separation of final products from inorganics and salts
(Korzeniowski et al., 1977; Burglova et al., 2016).
We investigated the scope of the new reaction using the conditions from entries 5 and 13
(Table 2.1) to synthesize a range of aryl bromides and iodides (Figure 2.1). The reaction worked
well with electron-withdrawing groups (EWG) such as trifluoromethyl (2b, 2h, 3k), ester (2d,
3b), nitro (2e, 3c), ketone (2k), aldehyde (2l), sulfone (2s), and pentafluorosulfanyl (3j and 3l).
Bromination of p-anisidine afforded 2j in 30% yield and generated several byproducts in the
aqueous phase (Figure 2.1) including the hydrogen abstraction product anisole (4a) and the
dimeric triazene 4b, diazo 4c, and biphenyl 4d. However, when we added 2 equiv of NaN3 prior
to reaction workup, GC/MS analysis of the reaction mixture revealed generation of 2j and 1azido-4-methoxybenzene. This indirectly demonstrates that a large amount of 4methoxybenzenediazonium remains unreacted in the aqueous layer, indicating that the electrondonating p-methoxy group deters the diazonium from decaying into the aryl radical intermediate.
Hence, diazonium decomposition can be considered the rate-limiting step (RLS) for this reaction.
When we extended the reaction time from 1 to 24 h, the yield of 2j increased to 44%. Increasing
the reaction temperature to 70 °C improved the yield of 2j to 84%. These results suggest the
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lower yields obtained for electron-rich anilines can be attributed to the high stability of the
diazonium intermediate at rt. m-anisidine generated 2x and 3h in low yields (26% and 24%).
Extending the reaction time and increasing the temperature did not increase reaction yields. We
detected no azide reaction product after addition of NaN3 to the aqueous layers, suggesting
extensive byproduct formation in these reactions.
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Figure 2.1. Aniline substrate scope. Key: (a) 23 °C, 24 h.; (b) 70 °C, 24 h, in a sealed vessel; (c)
CH3CN, 23 °C, 1 h; (d) CH3CN, 70 °C, 24 h, in a sealed vessel.
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Figure 2.2. Aqueous phase byproducts.
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Unexpectedly, for electron-rich anilines, reaction yields tended to increase when CH2I2
was used as the halogen source (3d vs 2j, 3g vs 2u), although for the latter reaction, the major
product was 1,3-dimethoxybenzene. Other relatively electron-rich anilines afforded the
corresponding iodides 3i, 3m, and 3n in moderate to good yields. We hypothesize that the
reaction generates iodide (Scheme 2.2) in situ, which can catalyze aryl radical formation as iodide
is a better reducing agent than acetate. The presence of iodide is also supported by the
observation that the solution developed a burgundy iodine color as a result of iodide oxidation
(Abeywickrema et al., 1987; Meyer et al., 1979).
4-Bromobenzoic acid (2c) was produced in only 10% yield (Figure 2.1); multiple
byproducts were detected via GC/MS, such as the triazene and azo dimers and the hydrogen
abstraction product benzoic acid. Adding NaN3 to the aqueous layer produced a large amount of
4-azidobenzoic acid, suggesting that the unreacted diazonium intermediate is not highly soluble
in CH2Cl2. When a water/CH3CN solvent system (Table 2.1, entry 9) was used, 2c was produced
in 43% yield. Moreover, when the temperature was increased to 70 °C for 24 h, the yield of 2c
increased to 90%. This result indicates that the low initial yield of 2c was due to poor solubility
and later decomposition of the diazonium intermediate in the organic layer. Amide 2i was also
produced in low yield (34%) using the CH2Cl2/water solvent system at rt. However, when we
used the water/CH3CN solvent system (Table 2.1, entry 9) at 70 °C for 24 h, the yield of 2i
increased to 91%. 4-Bromobenzonitrile (2a), 2-bromobenzonitrile (2p), and 3-bromobenzonitrile
(2t) were produced in yields ranging from 80 to 89%. 2-Bromobenzimidazole (2n) was produced
in 33% yield from the corresponding amine. The unsubstituted 4-aminosulfanilamide gave only
low yields (10−27%) of the aryl bromide reaction product 2v, whereas the fully substituted 4amino-N,N-dimethylbenzenesulfonamide afforded the corresponding reaction product 2w in high
(98%) yield. Pyridines 2m and 2o were produced in relatively low yields due to dimerization side
products.

29
Scheme 2.2. In Situ Iodide Formation

ICH2OAc + H2O → HI + CH2O + HOAc

For this reaction, it appears that electron-deficient anilines afford higher yields than
electron-rich anilines. However, increased reaction times and temperatures can improve the
yields for electron-rich anilines. Additionally, a H2O/CH3CN solvent system can increase yields
of aryl halides from anilines with low solubility in CH2Cl2. To gain insight into the mechanistic
details of this conversion, the reaction of 1a was conducted in the presence of 2 equiv of TEMPO
(2,2,6,6-tetramethylpiperidin-1-yl)oxyl); under these conditions 4-((2,2,6,6-tetramethylpiperidin1-yl)-oxy)benzonitrile (Scheme 2.3, 6a) was formed in 50% yield. These results indicate the
reaction proceeds through an aryl free radical resulting from homolytic bond cleavage of the
diazonzium cation.
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Scheme 2.3. Aryl Radical Trapping Experiment
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On the basis of the overall understanding of Sandmeyer-type reactions and previous
mechanistic investigations (Korzeniowski et al., 1977; Wang et al., 2016; Kochi et al., 1957) we
propose an SRN1-like mechanism (Scheme 2.4). First, the aniline reacts with NaNO2 to produce
diazonium salt intermediate A. Then, a single-electron transfer from acetate causes diazonium
decomposition to afford N2, aryl radical B, and acetoxy radical C. Subsequently, radical B
abstracts halide from the halogen source to produce the trichloromethyl radical, which then either
combines with the remaining acetoxy radical C to generate active ester D or dimerizes to produce
hexachloroethane E. Active ester D decomposes in aqueous conditions, and although we could
not directly detect D, we were able to detect minute amounts of phenyl acetate and large amounts
of E during the reaction, data which supports this mechanism (Korzeniowski et al., 1977). To
assess the proposed reaction mechanism (Scheme 2.4) and to gain further insight into the origin
of the effect of aryl substituents on diazonium degradation, we performed a computational study.
We have already described that substantial quantities of unreacted diazonium (A, Scheme 2.4)
intermediates remain in the aqueous layer for electron-rich anilines, consistent with the low yields
for these substrates. Thus, one can consider the RLS to be that of diazonium degradation via
homolytic bond cleavage to form a phenyl free radical (Scheme 2.4).
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Scheme 2.4. Proposed Mechanism for the Synthesis of Aryl Bromides and Iodides from Anilines
via Halogen Abstraction
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To explore the substituent effects of this reaction, a linear free energy relationship
(LFER) study using DFT calculations was conducted. Relative thermodynamic stabilities of
substituted diazonium cations and phenyl radicals compared to the unsubstituted phenyl
counterparts were modeled using the UB3LYP functional. Relative free energy differences
between substituted and unsubstituted substrates were obtained using the exchange reaction in
Scheme B1 (appendix B). A combination of 12 parasubstituted electron-donating and withdrawing groups (EWG) were modeled on aryl radical and diazonium aromatic rings. Hammet
plots were prepared by plotting the log (KR/KH), derived from the relative free energy differences,
calculated
using the exchange reaction in Scheme B1, versus Hammett substituent constants (Hansch et al.,
1991; McDaniel et al., 1958; Swain et al., 1968) σp (Figure 2.3) and σp+ (Figure B1). Full
computational details, calculations, and thermodynamic data are contained in appendix B.
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Figure 2.3. Hammet plot of calculated log(KR/KH) values vs σp values in CH2Cl2 solvent.
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As seen by the linear correlations in Figure 2.3 and Figure B1, the etiology of the
substituent effects on the degradation of aryl diazoniums to the corresponding aryl radicals is
affected in a consistent way. The relative free energy differences of the exchange reaction divided
by −1.36 kcal/mol represent the log (KR/KH) used in LFER plots (derivation is shown in appendix
B). The RLS (Scheme 2.4) involves a substantial decrease in positive charge in going from
diazonium cation to the free radical and should display a LFER with a large positive slope, ρ.
Figure 2.3 shows the log (KR/KH) versus σp Hammet substituent constants with good linear
correlation (R2 = 0.94), indicating the para EWG substituents are generating partial positive
character on the ipso aryldiazonium carbon with a combination of both inductive and resonance
effects. The slope in Figure 2.3 is greater than that of Figure B1, ρ = 8.8 and 6.3, respectively,
indicating greater substituent sensitivity to both inductive and resonance effects (contained in the
σp constants) as opposed to just resonance effects.
We next evaluated the bond lengths in order to establish whether a correlation is present
between aryl-substituent and aryldiazonium bond distance since increased bond lengths favor
homolytic bond cleavage. Figure B2 shows the change in bond lengths versus σp for the
substituted diazonium cations which revealed good correlation, R2 = 0.91. Moreover, when we
plotted the change in C−N aryldiazonium bond frequency versus σp (Figure B3), the electron-rich
aromatic rings have higher frequency C−N bond vibrations relative to electron deficit aromatic
rings, supporting a mechanism where the RLS involves homolytic bond cleavage. The picture
that emerges from the DFT calculations is one in which para EWGs weaken the ipso
carbon−diazonium bond, prompting homolytic bond cleavage to produce an aryl radical which
then abstracts a halogen atom. In cases such as 3d and 3n, we hypothesize that iodide generated
in situ catalyzes the formation of aryl radicals. Overall, the results from Figures 2.1, 2.3,
B1, and B2 demonstrate that the yield of aryl halide product is tuned in response to the electronwithdrawing and electrondonating ability of the aryl-ring substituents.

36
2.3 Conclusion
In conclusion, we have developed a Sandmeyer-type synthesis of aryl halides from
anilines. This metal-free transformation is operationally simple, tolerates a variety of functional
groups, and can be conducted under mild acidic conditions without the exclusion of air. This
transformation enables the generation of several aryl halide starting materials required for the
synthesis of various target antischistosomal aryl hydantoin target molecules.
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Chapter 3: Optimization of Antischistosomal Aryl Hydantoins

Abstract
Aryl hydantoins were identified in the early 1980's as a promising antischistosomal
chemotype. However, as exemplified by Ro 13-3978 (1), this compound series produced
antiandrogenic side effects in the host, a not unexpected outcome given their close structural
similarity to the antiandrogenic drug nilutamide. Building on the known SAR of these
antischistosomal aryl hydantoins, we now describe optimization of this compound series by
structural modifications designed to decrease inactivating oxidative Phase I metabolism and
antiandrogenic side effects. These aryl hydantoins had good in vitro ADME profiles with
calculated polar surface area (PSA) values of 49–87 Å, measured LogD7.4 values of 1.2–3.5,
aqueous kinetic solubilities of 25 to >100 µg/mL, and estimated plasma protein binding values of
6–92%. The two key advances in our optimization of 1 were replacing the hydrogen atoms of the
gem-dimethyl substructure with deuterium or fluorine atoms to slow Phase I metabolism and
swapping the aryl trifluoromethyl substituent with a difluoroethyl to abolish antiandrogenic
effects. The oral exposure of the most active compounds was high and prolonged. Although there
was no direct correlation between Cmax or AUC0-last values and antischistosomal activity,
compounds with the highest antischistosomal activities also had the highest exposures. We
identified 27 and 28 as potential single-dose aryl hydantoin drug development candidates.
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Figure 3.1 Optimization of SAR for Ro 13-3978 (1)
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3.1 Introduction
Schistosomiasis is a tropical parasitic disease (Hotez et al., 2008) caused by infections
with flukes of the genus Schistosoma, affecting as many as 200 million individuals worldwide,
with 779 million living at risk of infection (Steinmann et al., 2006; Colley at al. 2014).
Schistosoma mansoni, S. haematobium and S. japonicum cause the largest public health burden
(Gryseels, 2012; Colley et al., 2014). An estimated 1.4 million disability-adjusted life years
(DALYs) have been attributed to schistosomiasis using the most recent DALY metrics (Murray et
al., 2018). To reduce the chronic health burden, millions of school-aged children are treated each
year in the framework of “preventive chemotherapy” programs with praziquantel (PZQ) (Knopp
et al., 2013). PZQ is the only drug available for treatment of this disease, but it is rapidly
metabolized, rarely curative, and has little activity against juvenile schistosomula, the young
developmental stage of the parasite (Utzinger et al., 2011; Olliaro et al., 2014; Bergquist et al.,
2017). The widespread administration of PZQ could lead to problematic drug resistance (Melman
et al., 2009), possibly due to upregulation of the schistosomal homologue of the P-glycloprotein
drug transporter (Kasinathan and Greenberg, 2012). We have yet to discover a new
antischistosomal drug (Horton, 2003; Geary et al., 2010; Caffrey and Secor, 2011; Keiser and
Utzinger, 2012; Pedrique et al., 2013), although several antischistosomal lead compounds
(Njoroge et al., 2014; Mäder et al., 2018; Panic and Keiser, 2018; Caffrey et al., 2019) have been
identified in recent years.
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Figure 3.2. Aryl hydantoins Ro 13-3978 (1), 2-4, and nilutamide (N) and praziquantel (PZQ).
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Ro 13-3978 (1) (Figure 3.1) was the lead compound from a series of aryl hydantoins that
were investigated in the early to mid 1980s at Hoffmann La-Roche (Bernauer et al., 1980; Forget
et al., 1982; Hansen and Hafliger, 1983; Link and Stohler, 1984). As reported by Link and Stohler
(1984), 1 has high antischistosomal activity against S. mansoni, S. haematobium and S.
japonicum in a range of animal models. Confirming these data, we found that 1 had ED50 values
of 15 and 140 mg/kg against adult and juvenile S. mansoni in a mouse model (Keiser et al., 2015)
when it was administered as single oral doses. In this same schistosome mouse model, PZQ has
ED50 values ranging from 172 to 202 mg/kg (Keiser et al., 2011; Link and Stohler, 1984) against
adult schistosomes, and it has no significant activity against juvenile stages of the parasite. We
then found that 1 at concentrations up to 170 µM had almost no effect on ex vivo adult S.
mansoni (Keiser et al., 2015). Hydroxymethyl hydantoin 4 (AR40), the only metabolite of 1, is
completely inactive – thus, active metabolites do not seem to explain the striking difference
between the in vitro and in vivo antischistosomal activity of Ro 13-3978 (Keiser et al., 2015;
Wang et al., 2016).
Ro 13-3978 (1) and related hydantoins weakly inhibit dihydrotestosterone (DHT)induced cell proliferation in androgen-dependent cell lines (Wang et al., 2014; 2016) and produce
antiandrogenic side effects in the host (Bernauer et al., 1980), an unsurprising outcome given
their close structural similarity to the antiandrogenic drug nilutamide (N). However, N has only
weak antischistosomal activity in S. mansoni-infected mice (Keiser et al., 2010). As schistosome
species do not appear to have androgen receptors (AR) (Mendonça et al., 2000), these data led us
to hypothesize that for these aryl hydantoins, the structural requirements for antischistosomal
activity and AR binding are orthogonal.
Investigation of this aryl hydantoin compound series by Hoffmann La-Roche (Link and
Stohler, 1984) revealed that a combination of F, Cl, and CF3 groups at positions 3 and 4 of the
phenyl ring were optimal but that electron-donating groups such as methoxy and dimethylamino
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at these same positions diminished activity. They also showed that 4-imino derivatives and some
N1-substituted analogs were active, but we found that both of these underwent rapid Phase I
metabolism to the corresponding 4-oxo and N1-dealkyl hydantoins (Wang et al., 2014; 2016). We
also found that the hydantoin core of 1 is required for high antischistosomal activity and
discovered difluoromethyl (2) and pyridyl (3) hydantoins as promising analogs of 1; the former
appeared to be less antiandrogenic than 1 (Wang et al., 2016).
Building on this foundation, our two-fold objective was to decrease the inactivating
Phase I metabolism and the antiandrogenic effects of 1. To achieve the first goal, our strategy was
to incorporate fluorine (8-11, 28) or deuterium (12, 27) atoms in the gem-dimethyl substructure of
1. To diminish antiandrogenic effects, we incorporated substructures and functional groups
known to diminish ligand-AR interactions (Jung et al., 2010, Liu et al., 2010, Vinggaard et al.,
2008; Zhang et al., 2006; Van Dort and Jung, 2001) such as sulfonamide (7), additional aromatic
halogens (13, 14, 22, 23) and C=N bonds (20, 21). We now report physicochemical profiling, in
vitro ADME, antiandrogenic assessment, plasma exposure, and in vivo antischistosomal activities
of target compounds 5-28.
3.2 Chemistry
Target compounds 13, 19-21, 23, and 25 were obtained in 19-72% yields by hightemperature Ullmann-type couplings of the corresponding aryl bromides and iodides (27-32) and
hydantoin 33 with cuprous oxide (Li et al., 2004; Sambiagio et al., 2014; Thilmany et al., 2019)
in DMA (Scheme 3.1). The aryl iodide precursors 30-32 were synthesized from the
corresponding anilines by the method of Leas et al. (2017).
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Scheme 3.1a Ullmann coupling reactions to generate various target compounds

a

Reagents and conditions: (a) Cu2O, DMA, 150-180 °C; 24-48 h.
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Similarly, target compounds 6-11 were obtained in 12-45% yields by high-temperature
reactions between the corresponding aryl iodide 46 and hyantoins 40-45 with cuprous oxide in
DMA; likewise, 28 (29%) was obtained in a reaction between aryl bromide 47 and hydantoin 44
(Scheme 2). Hydantoins 40-45 were obtained in Bucherer-Bergs reactions (Ware, 1950; Konnert
et al., 2017) of the corresponding ketones 34-39 in 49-100% yields.
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Scheme 3.2a Hydantoin variations formed from Bucherer-Bergs reactions and then sequential
Ullmann coupling to generate desired aryl hydantoins

a

Reagents and conditions: (a) NaCN, (NH4)2CO3, aq. EtOH or MeOH, 60-90 °C, 24 h, then 10%

aq. HCl; (b) Cu2O, DMF, 150-180 °C; 24-48 h.
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Target compound 17 was obtained in a six-step sequence starting with nitration of
propanone 48 to form 49 in quantitative yield (Scheme 3.3). Conversion of 49 to geminal
difluoride 50 (100%) with Deoxo-Fluor followed by nitro reduction afforded aniline 51 (36%).
Following the method of Leas et al. (2017), 51 was converted into the corresponding aryl iodide
52 in 66% yield. N-arylation of 52 with hydantoin 33 and cuprous oxide in hot DMA afforded 17
in 13% yield.
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Scheme 3.3a Synthesis of compound 17

a

Reagents and conditions: (a) fuming HNO3, -45 °C; 1.5 h; (b) Deoxo-Fluor, rt to 85 °C, 24 h; (c)

Fe, HCl, aq. MeOH, rt, 24 h; (d) NaNO2, CH2I2, H2O, DCM, then AcOH, rt, 1 h; (e) 33, Cu2O,
DMA, 160 °C, 24 h.
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Target compounds 14, 15, 18, 22, and 26 were obtained in 18-90% combined yields in a
two-step sequence (Link et al., 1984; Zhang et al., 2006; Hroch et al., 2012) starting with in situ
formation of the corresponding aryl isocyanates from anilines 53-57 with triphosgene (Scheme
3.4). Anilines 55 and 56 were obtained by catalytic hydrogenation of the corresponding nitro
precursors. This was followed by reaction with amino acid 58 in aq. NaOH to form the
corresponding acyclic urea carboxylic acids that then cyclized to the target N3-aryl hydantoins
when exposed to 10% aq. HCl at 110 °C. In some instances, the urea carboxylic acid reaction
intermediates precipitated from the initial reactions after acidification, but these were not usually
purified, and were converted directly to the desired hydantoin reaction products.

51
Scheme 3.4a Synthesis of aryl hydantions via reaction of 2-aminoisobutyric acid with isocyanate
intermediates

a

Reagents and conditions: (a) triphosgene, EA/toluene, 0-25 °C to 80 °C, 16 h; (b) 1 M NaOH,

CH3CN, 0 °C to rt, 16 h; (c) 10% aq. HCl, 110 °C, 1-72 h.
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Target compound 24 was obtained by copper iodide-mediated cyclization of ester urea 59
to hydantoin 60 (56%) followed by nucleophilic aromatic substitution the latter with cuprous
cyanide (60%) (Scheme 3.5). Target compound 5 was obtained in 46% yield by acid-catalyzed
cyclization of urea carboxylic acid 61 (Wang et al., 2018). Target compounds 12, 16, and 27
were obtained as previously described (Leas and Vennerstrom patent, 2020)
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Scheme 3.5a Synthesis of aryl hydantoins 5 and 24

a

Reagents and conditions: (a) CuI, DBU, DMSO, 120 °C, 0.3 h; (b) CuCN, DMF, 120 °C, 16 h;

(c) 4M HCl, 110 °C, 12 h.

54
3.3 Physicochemical and in vitro ADME
We first consider the physicochemical and in vitro ADME properties of these analogs of
1 (Tables 3.1-3.2). The calculated polar surface area (PSA) values of between 49 and 87 Å2
indicate that the polarity of these compounds is unlikely to be a rate-limiting factor for membrane
permeability and oral bioavailability (Palm et al., 1997). The measured LogD7.4 values for the 5substituted analogs of 1 (Table 3.1) fell in the fairly narrow range of 2.6 to 3.5. Replacing the
hydrogen atoms with fluorine (8-10) or a trifluoromethyl group (11) in the gem-dimethyl
substructure of 1 increased LogD7.4 values by 0.3 to 0.8 units. The measured LogD7.4 values for
the N3-substituted analogs of 1 (Table 3.2) fell in the range of 1.2 to 3.3. Most compounds had
fairly high aqueous kinetic solubilities (≥ 50 µg/mL); only the spirocyclobutyl (5),
trifluoromethyl (10, 11), and chloro (23) analogs of 1 had solubilities ≤ 50 µg/mL.
For the 5-substituted derivatives of 1 (Table 3.1), the only compounds with estimated
plasma protein binding values ≥ 70% were the fluorinated derivatives 8-11 which had cPPB
values between 73 and 92%. For the N3-substituted analogs of 1 (Table 3.2), the only compounds
with protein binding values ≥ 60% were 23 and the pentafluorosulfanyl analog 25 with respective
cPPB values of 85 and 69%; notably, 23 (LogD7.4 3.3) was the most lipophilic N3-substituted
analog. With only two exceptions (spirocyclobutyl 5 and methylated pyridine 20), these
hydantoins had high metabolic stabilities.
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Table 3.1. Physicochemical, in vitro ADME, antiandrogenic, and antischistosomal data for
5-substituted 4-fluoro-3-trifluoromethylphenyl hydantoins

Compd

LogD7.4a

PSA

cPPB

Sol2.0/Sol6.5

h/m CLint

(Å2)b

(%)c

(µg/mL)d

(µL/min/mg

LAPC4
IC50 (µM)f

protein)e

S. mansoni
WBR (%)
1 x 100
mg/kg pog

1h

2.7

49.4

52.1

>100/>100

8/<7

11

95*

5

3.0

49.4

67.1

25-50/25-50

11/42

6.1

0

6

2.6

83.6

25.2

50-100/50-

<7/<7

>10

27

<7/<7

>10

26

<7/<7

9.0

35

<7/<7

4.2

92*

100
7

3.1

86.8

58.8

50-100/50100

8

3.0

49.4

72.9

50-100/50100

9

3.2

49.4

72.6

50-100/50100

a

10

3.5

49.4

91.5

25-50/25-50

<7/<7

5.2

100*

11

3.4

49.4

80.7

25-50/50-100

<7/<7

3.7

NDi

12

2.7

49.4

57.0

>100/>100

<7/<7

14

98*

LogD values were estimated by correlation of their chromatographic retention properties

using gradient HPLC (Lombardo et al., 2001)
b

calculated using ChemAxon JChem for Excel
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c

Protein binding values values were estimated by correlation of their chromatographic retention

properties on a human albumin column (Valko et al., 2003)
d

Compounds in DMSO were spiked into either pH 6.5 phosphate buffer or 0.01 M HCl (approx.

pH 2.0) and analyzed by nephelometry to determine a concentration range (Bevan and Lloyd,
2000).
e

in vitro intrinsic clearance measured in human and mouse liver microsomes

f

Cells were then exposed to 10 nM DHT for 24 h in the presence of varying concentrations of test

compounds.
g

Groups of five S. mansoni-infected NMRI mice were treated on day 49 post-infection with

compounds dissolved or suspended in SSV. At 21 d post-treatment, animals were sacrificed and
dissected to assess total worm burden reduction (WBR). *p <0.05 from the Kruskal–Wallis test
comparing the medians of the responses between the treatment and control groups.
h

data from Keiser et al. (2015) and Wang et al. (2016)

i

One mouse died 3 h after treatment and two mice died 2 d after treatment

ND = not determined
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Table 3.2. Physicochemical, in vitro ADME, antiandrogenic, and antischistosomal data for
N3-substituted aryl hydantoins

Compd

LogD7.4

PSA

cPPB

Sol2.0/Sol6.5

(Å2)

(%)

(µg/mL)

h/m CLint
(µL/min/mg
protein)

a

LAPC4
IC50

S. mansoni
WBR (%)

(µM)
1 x 100 mg/kg po

13

1.8

49.4

12.7

>100/>100

<7/7

8.3

64

14

2.4

49.4

54.3

50-100/50-100

<7/8

9.7

89*

15

1.2

83.6

5.9

50-100/>100

<7/<7

11

0

16

2.6

49.4

32.6

>100/>100

7/<7

>100

98*

17

2.9

49.4

ND

>100/>100

<7/7

>100

26

18

2.7

49.4

35.4

50-100/>100

<7/<7

18

NDa

19

2.9

58.6

51.7

50-100/50-100

<7/<7

12

NDb

20

2.2

62.3

20.5

>100/>100

<7/19

>10

21

21

1.6

62.3

9.6

>100/>100

<7/<7

ND

4

22

2.7

49.4

57.8

50-100/>100

<7/9

15

100*

23

3.3

49.4

84.5

25-50/25-50

<7/<7

0.29

2

24

2.8

73.2

24.2

50-100/50-100

<7/<7

>10

14

25

3.0

49.4

69.4

50-100/50-100

<7/<7

>10

43

26

2.5

67.9

42.5

50-100/>100

<7/<7

4.9

10

Two mice died 2 h after treatment and two were euthanized due to compound toxicity.

b

All mice were euthanized 1 d after treatment due to compound toxicity.
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c

no dose-response

*p <0.05 from the Kruskal–Wallis test comparing the medians of the responses between the
treatment and control groups.
ND = not determined
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3.4 Antiandrogenic activity
In vitro antiandrogenic activities were assessed by inhibition of dihydrotestosterone
(DHT)-induced androgen luciferase reporter activity in the LAPC4 cell line, a cell line with a
wild-type androgen receptor (AR). In this assay, the antiandrogen hydantoin drug nilutamide has
an IC50 of 0.52 µM (Wang et al., 2016). Consistent with our expectation, sulfone 6 and
sulfonamide 7 had no measurable antiandrogenic effects up to 10 µM (Table 3.1). Analogs with
fluoroalkyl groups at the 5-position had antiandrogenic effects similar to (8) or slightly greater (911) than that of 1. Hydantoin 1 and its hexadeutero derivative 12 had similar antiandrogenic
potencies. For the N3-substituted analogs in Table 3.2, replacing the trifluoromethyl group in 1
with a fluorine (13), bromine (14), methylsulfone (15) or trifluoromethoxy (19) had little effect
on antiandrogenic potency. Compounds with an aromatic C=N bond (20), an added aromatic
nitrile (24), or a pentafluorosulfanyl group (25) had no measurable antiandrogenic effects up to
10 µM (Table 3.2). The gem-difluoro 1,3-benzodioxole 26 was 2-fold more potent than 1,
whereas 23, the chlorinated derivative of 1, was a potent antiandrogen, similar to that of
nilutamide. The most striking finding was the complete lack of antiandrogenic effects for the
difluoroethyl (16) and difluoropropyl (17) derivatives of 1, even at concentrations up to 100 µM.
3.5 Antischistosomal activity
In vivo antischistosomal properties were assessed by measuring worm burden reduction
(WBR) in S. mansoni-infected mice. As we had previously observed for 1, none of the
compounds at concentrations up to 100 µM had activity against schistosomula or adult S.
mansoni in vitro (data not shown). Neither of the three 5,5-spirocyclo derivatives (5-7) of 1 had
significant antischistosomal activity (Table 3.1). Surprisingly, replacing the gem-dimethyl of 1
with a gem- difluoromethyl (8) reduced WBR from 95% to an insignificant 35%, whereas
replacing one of the 5-methyl groups with a difluoromethyl (9) or trifluoromethyl (10) maintained
high WBR values of 92 and 100%, respectively. However, trifluoroethyl substitution at this same
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position (11) led to a toxic hydantoin derivative. It is worth noting that the corresponding ethyl
hydantoin derivative of 11, while not toxic, was not very active with a WBR of 37% in adult
schistosomes at a 100mg/kg dose (data not shown). Finally, the hexadeutero derivative 12 was no
less active than 1.
The antischistosomal properties of the N3-substituted aryl hydantoins exhibit several
interesting trends (Table 3.2). Of these 14 compounds, only 14, 16, and 22 had high
antischistosomal activity, two (18, 19) were toxic, and the remaining compounds had none or
insignificant antischistosomal activity. In 14 and 16, the trifluoromethyl group of 1 was replaced
with a bromine atom or difluoroethyl group, respectively; in 22, an additional fluorine atom was
added ortho to the trifluoromethyl substituent of 1. For the closely related, but toxic analogs 18
and 19, the trifluoromethyl group of 1 was replaced with a trifluoroethyl or trifluoromethyoxy,
respectively. Interestingly, both 18 and 19 had trifluoromethyl groups removed by one atom from
the phenyl ring.
3.6 Frontrunner aryl hydantoins 27 and 28
Data for 27 and 28, two compounds which combine optimal substitution at the 5-position
and phenyl substructure of 1, are shown in Table 3.3. The first of these, compound 27, embodies
two key advances in our optimization of 1 – replacing the hydrogen atoms of the gem-dimethyl
substructure with deuteriums to slow Phase I metabolism (12) and swapping the trifluoromethyl
substituent with a difluoroethyl (16) to abolish antiandrogenic effects (LAPC4 IC50 >100 µM).
The second of these, 28, differs from 27 only in replacing one of the gem-dimethyl groups of 1
with a trifluoromethyl (10). As the data in Table 3.3 demonstrate, both 27 and 28 have excellent
in vitro ADME profiles and high in vivo antischistosomal activity, although the slightly more
hydrophobic and less soluble 28 does, like its analog 10, have antiandrogenic activity (LAPC4
IC50 2.9 µM). Thus, a 5-trifluoromethyl group seems to override the antiandrogenic-weakening
effect of a 3-difluoroethyl aryl substituent.
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The most active compounds were then tested against mice infected with adult and
juvenile S. mansoni (Table 3.4). At the lower 50 mg/kg dose, with the exception of 14 and 22,
these aryl hydantoins reduced WBR in adult S. mansoni-infected mice by 81-100% – a range
comparable to the WBR of 89-100% seen at the 100 mg/kg dose (Tables 3.1-3.3). As a whole,
the compounds were less active against juvenile S. mansoni, but at the 100 mg/kg dose, 9, 10, 12,
16, 27, and 28 reduced WBR by 62-100%; notably, 27 and 28 reduced WBR by 100% at both the
100 and 50 mg/kg doses.
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Table 3.3. Physicochemical, in vitro ADME, antiandrogenic, and antischistosomal data for
frontrunner aryl hydantoins 27 and 28.

Compd

LogD7.4

PSA

cPPB

Sol2.0/Sol6.5

(Å2)

(%)

(µg/mL)

h/m CLint
(µL/min/mg

LAPC4
IC50 (µM)

protein)

S. mansoni
WBR (%)
1 x 100
mg/kg po

27

2.5

49.4

ND

>100/>100

<7/<7

>100

100*

28

3.4

49.4

ND

50-100/50-

<7/<7

2.9

100*

100

*p <0.05 from the Kruskal–Wallis test comparing the medians of the responses between the
treatment and control groups.
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Table 3.4. Antischistosomal activity of selected aryl hydantoins against adult and juvenile S.
mansoni in the infected mouse model.
adult S. mansoni WBR (%)
Compd

a

juvenile S. mansoni WBR (%)

50 mg/kg po

100 mg/kg po

50 mg/kg po

1a

78*

64*

0

9

95*

62*

ND

10

81*

99*

7.1

12

100*

86*

9

14

50

29

ND

16

98*

89*

50

22

65*

23

ND

27

100*

100*

100*

28

100*

100*

100*

data from Keiser et al., 2015

*p <0.05 from the Kruskal–Wallis test comparing the medians of the responses between the
treatment and control groups.
ND = not determined
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3.7 Mouse Exposure
For these aryl hydantoins, none of the compounds had measurable in vitro activity
although several had high in vivo activity. Therefore, to see if there was a correlation between
antischistosomal efficacy and plasma exposure and to assess the effect of aryl hydantoin structure
on pharmacokinetics, the most active aryl hydantoins (9, 10, 12, 14, 16, 22, 27, and 28) were
administered to non-infected mice at single oral doses of 100 mg/kg (Table 3.5). We made the
assumption that exposure profiles generated in non-infected mice provided a reasonable
estimation of exposure in S. mansoni-infected mice.
With the exception of 14, the oral exposure of all of the tested compounds was high and
prolonged, with plasma concentrations remaining above 10 μg/mL for the duration of the 48 h
sampling period (Table 3.5). The flat profiles (Figure 3.3) are likely to be due to the low intrinsic
clearance as predicted in mouse liver microsomes and potentially prolonged absorption given the
high dose of 100 mg/kg. Cmax values ranged from 31 to 43 µg/mL and AUC0-last values ranged
from 704 to 1815 µg/mL.h. For this set of compounds, there was no correlation between Cmax or
AUC0-last values and antischistosomal activity (WBR values).
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Figure 3.3. Plasma concentration versus time profiles of 1 (pink), 9 (blue), 10 (orange), 12
(violet), 14 (brown), 16 (dark green), 22 (lime green), 27 (black) and 28 (red) following oral
administration of 100 mg/kg to male Swiss outbred mice. Symbols represent individual data
points and the lines represent the mean profiles.
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Table 3.5. Exposure parameters for selected aryl hydantoins in male Swiss outbred mice
following oral administration of 100 mg/kg.

a

Compd

Cmax (µg/mL)

Tmax (h)

AUC0-last (µg/mL.h)

1a

36

24

795

9

42

24

1646

10

28

24

966

12

43

30

1815

14

37

3.0

704

16

40

7.0

1561

22

31

7.0

1198

27

41

7.0

1799

28

34

24

1286

data from Wang et al. (2016)

c.n.d. = could not determine
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3.8 Summary
Aryl hydantoins 5-28 had calculated polar surface area (PSA), measured LogD7.4,
aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of
good ADME profiles. Replacing the trifluoromethyl substituent of 1 with either difluoroethyl
(16) or difluoropropyl (17) substructures abolished antiandrogenic effects. Replacing the
hydrogen atoms of the gem-dimethyl substructure of 1 with deuterium or fluorine atoms slowed
Phase I metabolism, increased exposure, and in most cases, increased antischistosomal activity.
With only one exception, the oral exposure of all of the most active compounds was high and
prolonged following a single 100 mg/kg oral dose, although there was no correlation between
Cmax or AUC0-last values and antischistosomal activity (WBR values). We identified 27 and 28 as
potential single-dose aryl hydantoin drug development candidates.
3.9 Experimental Section
3.9.1 Kinetic Solubility
Compounds in DMSO (10 mg/mL) were diluted into either pH 6.5 phosphate buffer or
0.01 M HCl (approx. pH 2.0) with the final DMSO concentration being 1%. Samples were then
analysed via nephelometry to determine a solubility range (Bevan and Lloyd, 2000).
3.9.2 Partition Coefficient.
Partition coefficient values (LogD) of the test compounds were estimated by correlation
of their chromatographic retention properties against the characteristics of a series of standard
compounds with known partition coefficient values using gradient HPLC (modification of a
method reported by Lombardo et al., 2001).
3.9.3 Plasma Protein Binding.
Plasma protein binding values of the test compounds were estimated by correlation of
their chromatographic retention properties on a human albumin column against the characteristics
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of a series of standard compounds with known protein binding values. The method employed is a
gradient HPLC based derivation of the method developed by Valko et al. (2003).
3.9.4 In Vitro Metabolic Stability.
As described by Charman et al. (2020), metabolic stability assays were performed by
incubating test compounds in liver microsomes at 37 °C and 0.4 mg/mL protein concentration.
The metabolic reaction was initiated by the addition of an NADPH-regenerating system and
quenched at various time points over a 60 min incubation period by the addition of acetonitrile
containing diazepam as internal standard. Control samples (containing no NADPH) were
included (and quenched at 2, 30 and 60 min) to monitor for potential degradation in the absence
of cofactor.
3.9.5 Mouse Exposure Studies.
The systemic exposure of the aryl hydantoins was studied in non-fasted male Swiss
outbred mice weighing 25–33 g. Mice had access to food and water ad libitum throughout the
pre- and post-dose sampling period. Formulations were prepared by dispersing the aryl
hydantoins in Tween 80 and then adding ethanol and Milli-Q water (final composition 7% v/v
Tween 80, 3% v/v ethanol). Following vortexing and sonication, samples formed uniform
suspensions (9, 10, 12, 14, 16, 22, 27, and 28). Compound formulations were mixed by inverting
the tubes prior to drawing each dosing volume. All animals were dosed orally by gavage (10
mL/kg dose volume) within 1 h of formulation preparation. Following administration, blood
samples were collected from 0.25-48 h post-dose (n = 2 mice per time point). A maximum of two
samples were obtained from each mouse, with samples being taken either via submandibular
bleed (approximately 120 μL; conscious sampling) or terminal cardiac puncture (0.6 mL; while
mice were anaesthetised using inhaled Isoflurane). No urine samples were collected as mice were
housed in bedded cages during the study. Blood was collected directly into polypropylene
Eppendorf tubes containing heparin as anticoagulant and stabilization cocktail (containing
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Complete® (a protease inhibitor cocktail), potassium fluoride and EDTA) to minimize the
potential for ex vivo degradation of the aryl hydantoins in blood/plasma samples. Once collected,
blood samples were centrifuged immediately, supernatant plasma was removed, and stored at -80
°C until analysis by LCMS. Plasma concentration-time data were analyzed using
noncompartmental methods (PKSolver Version 2.0).
3.9.6 Antischistosomal Screen.
As described by Lombardo et al. (2019), cercariae of S. mansoni were obtained from
infected Biomphalaria glabrata. NMRI mice were infected subcutaneously with approximately
100 S. mansoni cercariae. At 49 d after infection, groups of four mice were treated with single
100 mg/kg oral doses of compounds in a 7% (v/v) Tween 80% and 3% (v/v) ethanol vehicle (10
mL/kg). Untreated mice (n = 8) served as controls. At 21 d post-treatment, animals were killed
by the CO2 method and dissected. Worms were removed by picking, then sexed and counted.
3.9.7 Androgen-Dependent Cell-based Assay.
As described by Jones and Diamond (2008), LAPC4 cells were cultured in phenol red
free RPMI 1640 media supplemented with antibiotics and 10% FBS. For all transfections, pools
of cells were transfected using Lipofectamine Plus (Invitrogen) with PSA-luciferase (Bolton et al.
2007) and pRL-SV40 (Promega) as a normalization control. The following day, the cells were replated, 0.3 nM DHT and test compounds were added, and 24 h later luciferase production was
measured (Dual luciferase assay kit; Promega), normalizing the firefly signal to the renilla signal.
Mean-effect plots (log[compound] vs. log[fractional effect]) were generated to determine the
IC50 values for each test compound or combinations of test compounds at constant ratios.
3.9.8.1 Aryl hydantoin synthesis
Melting points are uncorrected. 1D 1H and 13C NMR spectra were recorded on 400, 500,
and 600 MHz spectrometers using CDCl3 or DMSO-d6 as solvents. All chemical shifts are
reported in parts per million (ppm) and are relative to internal (CH3)4Si (0 ppm) for 1H and CDCl3
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(77.2 ppm) or DMSO-d6 (39.5 ppm) for 13C NMR. EI GC-MS data were obtained using a
quadrupole mass spectrometer with 30 m DB-XLB type columns and a He flow rate of 1 mL/min.
Silica gel (sg) particle size 32−63 μm was used for all flash column chromatography. Reported
reaction temperatures are those of the oil bath. Combustion analysis confirmed that all target
compounds have a purity of at least 95%.
7-[4-fluoro-3-(trifluoromethyl)phenyl]-5,7-diazaspiro[3.4]octane-6,8-dione (5). 1-[3-[4Fluoro-3-(trifluoromethyl)phenyl]ureido]cyclobutanecarboxylic acid (61) (Wu et al., 2018
BMCL) was suspended in 4 M HCl (25 mL) and heated at 110 °C for 12 h. The reaction mixture
was concentrated and the resulting precipitate was crystallized from a mixture of EtOH (4 mL)
and H2O (20 mL) and then recrystallized from diethyl ether (2 mL) to give 5 (1.256 g, 46 %) as a
white solid. mp 151–152 oC. 1H NMR (500 MHz, DMSO-d6) δ 1.71 – 1.87 (m, 1H), 1.87 – 2.05
(m, 1H), 2.36 (qd, J = 9.9, 2.6 Hz, 2H), 2.52 – 2.59 (m, 2H), 7.65 (t, J = 9.7 Hz, 1H), 7.71 – 7.83
(m, 1H), 7.88 (dd, J = 6.7, 2.5 Hz, 1H), 9.00 (s, 1H). 13C NMR (125 MHz, DMSO-d6) δ 13.39,
32.40, 60.03, 116.69 (qd, J = 32.8, 13.4 Hz), 117.70 (d, J = 21.7 Hz), 122.23 (q, J = 272.0 Hz),
125.52 (q, J = 5.2 Hz), 128.84 (d, J = 3.3 Hz), 133.42 (d, J = 9.2 Hz), 153.74, 157.46 (dq, J =
254.3, 2.3 Hz), 175.45. Anal Calcd for C13H10F4N2O2: C, 51.66; H, 3.34; N, 9.27; Found: C,
51.87; H, 3.45; N, 9.05.
3-(4-Fluoro-3-(trifluoromethyl)phenyl)-8-thia-1,3-diazaspiro[4.5]decane-2,4-dione-8,8dioxide (6). Step 1. To a solution of tetrahydro-4H-thiopyran-4-one 1,1-dioxide (34) (650 mg,
4.4 mmol) and (NH4)2CO3 (1.268 g, 13.2 mmol) in water (30 mL) was added NaCN (431 mg, 8.8
mmol) dissolved in a minimal amount of water. The reaction mixture was heated at 90 °C for 24 h
and cooled to rt. 10% HCl (50 mL) was added and a solid precipitated once the solution was
cooled to 10 °C. The residue was filtered and washed with water (4 x 20 mL) and dried overnight
in vacuo to afford 8-thia-1,3-diazaspiro[4.5]decane-2,4-dione-8,8-dioxide (40) (550 mg, 57%) as
an off-white microcrystalline solid. mp 320 oC dec. 1H NMR (400 MHz, DMSO-d6) δ 2.10 (d, J =
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13.9 Hz, 2H), 2.25 (ddd, J = 15.1, 11.4, 4.2 Hz, 2H), 3.16 – 3.30 (m, 4H), 8.57 (s, 1H), 10.89 (s,
1H). 13C NMR (100 MHZ, DMSO-d6) δ 31.95, 46.45, 59.06, 155.95, 176.59. Step 2. To a
solution of 40 (502 mg, 2.3 mmol) and Cu2O (165 mg, 1.2 mmol) in DMA (10 mL) was added 1fluoro-4-iodo-2-(trifluoromethyl)benzene (46) (858 mg, 3.0 mmol). After it was heated at 160 oC
for 24 h, the solvent was evaporated in vacuo. The residue was purified by sg chromatography
(hexane to EA) to afford 6 (207 mg, 24%) as a white amorphous solid. mp 242–245 °C. 1H NMR
(400 MHz, DMSO-d6) δ 2.38 (dd, J = 8.3, 4.1 Hz, 4H), 3.32 – 3.40 (m, 4H), 7.68 (t, J = 9.7 Hz,
1H), 7.84 (ddd, J = 8.9, 4.5, 2.6 Hz, 1H), 7.94 (dd, J = 6.7, 2.5 Hz, 1H), 9.22 (s, 1H). 13C NMR
(125 MHz, DMSO-d6) δ 31.86, 46.39, 58.13, 116.74 (dq, J = 32.5, 13.8), 117.81 (d, J = 21.3),
122.23 (q, J = 271.3), 126.00 (d, J = 5.0), 128.50 (d, J = 2.5), 133.90 (d, J = 8.8), 153.94, 157.77
(d, J = 253.8), 173.66. Anal. Calcd for C14H12F4N2O4S: C, 44.21; H, 3.18; N, 7.37. Found: C,
44.40; H, 3.12; N, 7.43.
8-(Ethylsulfonyl)-3-(4-fluoro-3-(trifluoromethyl)phenyl)-1,3,8-triazaspiro[4.5]decane-2,4dione (7). Step 1. To a solution of 1-(ethylsulfonyl)piperidin-4-one (35) (Ellis et al., (2008)
(1.740 g, 9.1 mmol), (NH4)2CO3 (2.0 g, 20.8 mmol) in H2O (10 mL) and EtOH (10 mL) was
added NaCN (892 mg, 18.2 mmol) dissolved in a minimal amount of water and the reaction
mixture was heated at 60 oC for 24 h. After cooling to rt, 10% aq. HCl was added until a pH of 6
was reached. The solution was cooled in an ice bath and a solid precipitated which was filtered
and washed with H2O (3 x 20 mL) and then dried in vacuo to yield 8-(ethylsulfonyl)-1,3diazaspiro[4.5]decane-2,4-dione (41) (2.081 g, 88%) as a crude white solid. 1H NMR (400 MHz,
DMSO-d6) δ 1.22 (t, J = 7.4 Hz, 3H), 1.65 (d, J = 13.5 Hz), 1.82 (td, J = 4.4, 13.5 Hz, 2H), 3.10
(m, 4H), 3.55 (dt, J = 4.3, 12.7 Hz, 2H), 8.54 (s, 1H), 10.75 (s, 1H). Step 2. To a solution of 41
(442 mg, 1.7 mmol) and Cu2O (175 mg, 0.84 mmol) in DMA (10 mL) was added 46 (736 mg, 2.5
mmol). The reaction mixture was heated to 150 oC for 48 h under Ar. Then solvent was
evaporated in vacuo and the residue was purified by sg chromatography (hexane to EA/hexane
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1:1) and recrystallized (CH3CN/H2O 1:10), filtered and dried in vacuo to afford 7 (150 mg, 21%)
as a white crystalline solid. mp 226–228 oC. 1H NMR (400 MHz, DMSO-d6) δ 1.24 (t, J = 7.3 Hz,
3H), 1.86 – 2.02 (m, 4H), 3.11 (q, J = 7.3 Hz, 2H), 3.22 (ddd, J = 3.5, 10.3, 13.2 Hz, 2H), 3.56 –
3.66 (m, 2H), 7.67 (t, J = 9.7 Hz, 1H), 7.79 – 7.86 (m, 1H), 7.93 (dd, J = 2.5, 6.7 Hz, 1H), 9.20 (s,
1H). 13C NMR (125 MHz, DMSO-d6) δ 7.60, 32.83, 41.01, 43.29, 58.61, 116.71 (dd, J = 13.7,
19.2 Hz) 117.75 (d, J = 21.7 Hz), 122.24 (d, J = 272.6 Hz), 125.87 (d, J = 5.2 Hz), 128.66 (d, J =
3.4 Hz), 133.74 (d, J = 9.3 Hz), 154.00, 157.65 (d, J = 255.0 Hz), 174.39. Anal. Calcd for
C16H17F4N3O4S: C, 45.39; H, 4.05; N, 9.93. Found: 45.81; H, 4.00; N, 10.14.
3-(4-Fluoro-3-(trifluoromethyl)phenyl)-5,5-bis(fluoromethyl)imidazolidine-2,4-dione (8).
Step 1. To a solution of 1,3-difluoropropan-2-one (36) (550 mg, 5.8 mmol), (NH4)2CO3 (1.123 g,
11.7 mmol), H2O (10 mL) and EtOH (10 mL) in a pressure flask, was added NaCN (679 mg, 13.9
mmol) dissolved in a minimal amount of water. The vessel was sealed and it was heated at 60 oC
for 24 h. 10% HCl was added until a pH of 6 was reached. The solution was concentrated in
vacuo and extracted with EA (4 x 30 mL). The organic layer was dried with brine and MgSO4
and the solvent was evaporated in vacuo to yield 5,5-bis(fluoromethyl)imidazolidine-2,4-dione
(42) (950 mg, 100%) as an orange-brown solid which was used in the next step without further
purification. 1H NMR (400 MHz, DMSO-d6) δ 4.43 (d, J = 9.6 Hz, 1H), 4.57 (dd, J = 9.7, 17.2
Hz, 2H), 4.71 (d, J = 9.7 Hz, 1H), 8.49 (s, 1H). Step 2. To a solution of 42 (950 mg, 5.8 mmol)
and Cu2O (518 mg, 3.6 mmol) in DMA (20 mL) in a pressure flask was added 46 (2.098 g, 5.9
mmol). The vessel was sealed and the mixture heated to 170 oC for 48 h. After cooling to rt, the
solvent was evaporated in vacuo. The residue was purified by sg chromatography (hexane to
EA/hexane 1:1) and recrystallized (ether/hexane 1:10) to afford 8 (221 mg, 12%) as a pale
orange-white crystalline solid. mp 122–125 oC. 1H NMR (500 MHz, DMSO-d6) δ 4.67 (d, J = 9.7
Hz, 1H), 4.79 (dd, J = 9.8, 19.4 Hz, 2H), 4.90 (d, J = 9.8 Hz, 1H), 7.69 (t, J = 9.7 Hz, 1H), 7.75 –
7.81 (m, 2H), 7.83 (dd, J = 2.5, 6.6 Hz, 1H) 9.31 (s, 1H). 13C NMR (125 MHz, DMSO-d6) δ
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65.37 (t, J = 18.9 Hz), 81.31 (d, J = 6.0 Hz), 82.70 (d, J = 5.9 Hz), 117.47 (dd, J = 13.7, 33.2 Hz),
118.65 (d, J = 21.8 Hz), 122.58 (d, J = 273.1 Hz), 125.73 – 125.89 (m), 128.58 (d, J = 3.4 Hz),
133.88 (d, J = 9.5 Hz), 154.96, 158.30 (d, J = 255.8 Hz) 169.87 (t, J = 5.1 Hz). Anal. Calcd for
C12H8F6N2O2: C, 44.19; H, 2.47; N, 8.59. Found: C, 44.22; H, 2.43; N, 8.78.
5-(Difluoromethyl)-3-(4-fluoro-3-(trifluoromethyl)phenyl)-5-methylimidazolidine-2,4-dione
(9). Step 1. To a pressure flask were added 1,1-difluoropropan-2-one (37) (2.375 g, 25.3 mmol),
(NH4)2CO3 (4.900 g, 51.0 mmol), NH4Cl (2.770 g, 51.8 mmol), H2O (10 mL) and EtOH (10 mL)
and the solution was stirred for 10 min. NaCN (2.598 g, 53.0 mmol) was dissolved in a minimal
amount of water and added to the mixture. The vessel was sealed and heated at 70 oC for 24 h.
After cooling to rt, 10% HCl was added until a pH of 1 was reached. The solution was
concentrated and extracted with EA (3 x 30 mL). The organic layer was washed with brine, dried
with MgSO4 before solvent removal in vacuo to afford 5-(difluoromethyl)-5methylimidazolidine-2,4-dione (43) (2.982 g, 72%) as an orange microcrystalline solid. 1H NMR
(400 MHz, DMSO) δ 1.37 (s, 3H), 6.15 (t, J = 54.6 Hz, 1H), 8.47 (s, 1H), 11.01 (s, 1H). Step 2.
A stirred solution of 46 (3.411 g, 11.8 mmol), 43 (1.684 g, 10.3 mmol), Cu2O (753 mg, 5.3
mmol), and DMA (10 mL) was sealed in a pressure vessel and heated to 180 oC for 24 h. After
solvent removal in vacuo, the residue was purified by sg chromatography (hexane to hexane/EA
1:1) to afford a solid that was crystallized (Et2O/hexane 1:5) to give 9 (1.5 g, 45%) as a white
microcrystalline solid. mp 110–112 oC. 1H NMR (500 MHz, DMSO) δ 1.54 (s, 3H), 6.34 (t, J =
54.7 Hz, 1H), 7.69 (t, J = 9.7 Hz, 1H), 7.75 – 7.84 (m, 1H), 7.88 (dd, J = 2.5, 6.6 Hz, 1H), 9.24 (s,
1H). 13C NMR (125 MHz, DMSO) δ 16.00, 62.34 (t, J = 21.4 Hz), 114.06 (t, J = 246.2 Hz),
116.85 (dd, J = 13.4, 33.0 Hz), 117.98 (d, J = 21.8 Hz), 122.07 (d, J = 272.4 Hz), 125.59 (d, J =
4.8 Hz), 128.11 (d, J = 3.5 Hz), 133.55 (d, J = 9.4 Hz), 154.24, 157.77 (d, J = 257.0 Hz), 169.78 –
170.52 (m). Anal. Calcd for C12H8F6N2O2 0.5 H2O: C, 43.00; H, 2.71; N, 8.36. Found: C, 43.00;
H, 2.36; N, 8.43.
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3-(4-Fluoro-3-(trifluoromethyl)phenyl)-5-methyl-5-(trifluoromethyl)imidazolidine-2,4-dione
(10). Step 1. To a solution of 1,1,1-trifluoropropan-2-one (38) (1.520 g, 13.6 mmol), (NH4)2CO3
(2.784 g, 29 mmol), and NH4Cl (2.894 g, 54.1 mmol) in H2O (10 mL) and MeOH (10 mL) was
added NaCN (1.329 g, 27.1 mmol) dissolved in a minimal amount of water. The reaction mixture
was heated at 60 oC for 24 h. 10% HCl was added until a pH of 6 was reached. The solution was
then concentrated and extracted with EA (4 x 30 mL). The organic layer was dried with brine and
MgSO4. Evaporation of solvents in vacuo afford 5-methyl-5-(trifluoromethyl)imidazolidine-2,4dione (44) (Moore et al., 2008) (1.200 g, 49%) as a crude red semi-solid. 1H NMR (400 MHz,
DMSO-d6) δ 1.53 (m, 3H), 8.90 (s, 1H), 11.33 (s, 1H). Step 2. To a solution of 44 (834 mg, 4.6
mmol) and Cu2O (380 mg, 2.7 mmol) in DMA (10 mL) was added 46 (698 mg, 5.9 mmol). The
vessel was sealed and the mixture heated to 170 oC for 48 h. After cooling to rt, the solvent was
evaporated in vacuo. The residue was purified by sg chromatography (hexane to EA/hexane 1:1)
and recrystallized (ether/hexane 1:10) to afford 10 (570 mg, 36%) as a white crystalline solid. mp
112–115 oC. 1H NMR (400 MHz, DMSO-d6) δ 1.72 (s, 3H), 7.70 (t, J = 9.7 Hz, 1H), 7.82 (m,
1H), 7.92 (dd, J = 2.5, 6.5 Hz, 1H), 9.68 (s, 1H). 13C NMR (125 MHz, DMSO-d6) δ 16.34, 62.67
(q, J = 29.2 Hz), 117.07 (q, J = 15.7 Hz), 118.20 (d, J = 21.7 Hz), 121.65 (d, J = 157.3 Hz),
123.87 (d, J = 162.2 Hz), 125.86 (d, J = 5.5 Hz), 127.78 (d, J = 3.5 Hz), 133.77 (d, J = 9.5 Hz),
154.09, 158.08 (d, J = 255.9 Hz), 167.81. Anal. Calcd for C12H7F7N2O2: C, 41.88; H, 2.05; N,
8.14. Found: C, 41.69; H, 2.14; H, 8.21.
3-(4-Fluoro-3-(trifluoromethyl)phenyl)-5-methyl-5-(2,2,2-trifluoroethyl)imidazolidine-2,4dione (11). Step 1. To a pressure flask were added 4,4,4-trifluorobutan-2-one (39) (1.0 g,

7.93 mmol), (NH4)2CO3 (2.3 g, 23.9 mmol), H2O (10 mL), and EtOH (10 mL) and the
solution stirred for 10 min. NaCN (779 mg, 15.9 mmol) was dissolved in a minimal
amount of water and added to the mixture. The reaction flask was sealed and heated at 60
o

C for 24 h. The reaction was cooled to rt and 10% HCl was added until a pH of 1 was
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reached. The solution was concentrated in vacuo and extracted with EA (3 x 30 mL). The
combined organic layers were washed with brine and dried with MgSO4 and the solvent
was removed in vacuo to afford crude 5-methyl-5-(2,2,2-trifluoroethyl)imidazolidine-2,4dione (45) (640 mg, 64%) as an orange residue which was not further purified. Step 2. A
mixture of 46 (1.553 g, 5.355 mmol), 45 (500 mg, 2.55 mmol), Cu2O (185 mg, 1.29
mmol), and DMA (10 mL) were sealed in a pressure vessel and heated to 160 oC for 24 h.
After solvent removal in vacuo, the residue was purified by sg chromatography (hexane
to hexane/EA 1:1) gave a solid which was recrystallized (Et2O/hexane 1:5) to afford 11
(374 mg, 41%) as a white microcrystalline solid. mp 146–148 oC. 1H NMR (600 MHz,
DMSO) δ 1.52 (s, 3H), 2.83 (dq, J = 11.1, 15.6 Hz, 1H), 2.98 (dq, J = 11.1, 15.6 Hz, 1H),
7.69 (t, J = 9.6 Hz, 1H), 7.72 – 7.77 (m, 1H), 7.84 (dd, J = 2.5, 6.5 Hz, 1H), 8.96 (s, 1H).
C NMR (150 MHz, DMSO) δ 23.32, 57.36 (d, J = 2.3 Hz), 116.86 (qd, J = 13.6, 32.9
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Hz), 118.03 (d, J = 21.9 Hz), 122.07 (q, J = 272.2 Hz), 125.36 (d, J = 4.8 Hz), 125.54 (q,
J = 278.2 Hz), 128.39 (d, J = 3.2 Hz), 133.31 (d, J = 9.3 Hz), 153.58, 157.69 (dd, J = 2.3,
254.8 Hz), 173.78. Anal. Calcd for C13H9F7N2O2: C, 43.59; H, 2.53; N, 7.82. Found: C,
43.36; H, 2.65; N, 7.58.
3-(3,4-Difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (13). A solution of 1,2-difluoro-4iodobenzene (27) (2.358 g, 9.8 mmol), 5,5-dimethylimidazolidine-2,4-dione (33) (1.622 g, 12.7
mmol), Cu2O (762 mg, 5.3 mmol), and DMA (15 mL) was sealed in a pressure vessel and heated
to 180 oC for 24 h. After solvent removal in vacuo, the residue was purified by sg
chromatography (hexane to hexane/EA 1:1) giving a solid which was recrystallized (Et2O/hexane
1:5) to give 13 (1.50 g, 64%) as a white microcrystalline solid. mp 106–108 oC. 1H NMR (500
MHz, CDCl3) δ 1.55 (s, 6H), 6.22 (s, 1H), 7.21 – 7.30 (m, 2H), 7.33 – 7.42 (m, 1H). 13C NMR
(125 MHz, CDCl3) δ 25.29, 58.67, 115.64 (d, J = 20.3 Hz), 117.43 (d, J = 18.3 Hz), 122.20 (dd, J
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= 6.7, 3.8 Hz), 127.82 (dd, J = 8.1, 3.7 Hz), 148.90 (dd, J = 40.9, 13.0 Hz), 150.90 (dd, J = 40.3,
13.0 Hz), 175.65. Anal. Calcd for C11H10F2N2O2: C, 55.00; H, 4.20; N, 11.66. Found: C, 55.00; H,
4.14; N, 11.59.
3-(3-Bromo-4-fluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (14). Step 1. To a solution
of triphosgene (1.562 g, 5.3 mmol) in toluene (20 mL) at rt was added slowly a solution of 3bromo-4-fluoroaniline (53) ( 2.5 g, 13.2 mmol) in EA (10 mL). The reaction mixture was then
heated to 80 oC for 16 h. After cooling to rt, the solvent was removed in vacuo to afford the
corresponding isocyanate as a yellow semi-solid which was dissolved in CH3CN (10 mL). This
solution was added dropwise to a stirring solution of 2-aminoisobutyric acid (58) (1.544 g, 15.0
mmol) in 1 M NaOH (20 mL) at 0 °C. After the reaction mixture was stirred at rt for 16 h, the
reaction mixture was concentrated and the aq. layer washed with EA (30 mL). The aq. layer was
then concentrated and the pH was adjusted to 2 with concentrated HCl and then cooled in an ice
bath. The resulting precipitate was filtered and washed with H2O (2 x 20 mL) to afford 2-(3-(3bromo-4-fluorophenyl)ureido)-2-methylpropanoic acid (1.277 g, 40%) as a white crystalline solid
which was used in the next step without further purification. mp 169–171 oC. 1H NMR (500
MHz, DMSO-d6) δ 1.41 (s, 6H), 6.55 (s, 1H), 7.10 – 7.31 (m, 2H), 7.88 (dd, J = 2.6, 6.4 Hz, 1H),
8.68 (s, 1H), 12.42 (s, 1H). 13C NMR (126 MHz, DMSO-d6) δ 25.26, 54.91, 107.51 (d, J = 21.4
Hz), 116.52 (d, J = 22.9 Hz), 118.25 (d, J = 6.8 Hz), 121.32, 137.82 (d, J = 2.7 Hz), 152.90 (d, J
= 238.6 Hz), 154.12, 176.13. Step 2. 2-(3-(3-Bromo-4-fluorophenyl)ureido)-2-methylpropanoic
acid (600 mg, 1.9 mmol) was added to 10% HCl (15 mL) and the stirring mixture was heated to
110 °C in a pressure tube for 16 h. The mixture was then cooled 10 °C after which 14 (544 mg,
95%), a white microcrystalline solid, was filtered, washed with H2O (3 x 20 mL), and dried in
vacuo. mp 167–170 oC. 1H NMR (500 MHz, DMSO-d6) δ 1.40 (s, 6H), 7.46 – 7.53 (m, 2H), 7.81
(dd, J = 2.3, 6.4 Hz, 1H), 8.61 (s, 1H). 13C NMR (125 MHz, DMSO-d6) δ 24.61, 57.86, 107.51 (d,
J = 22.3), 116.62 (d, J = 23.4 Hz), 128.31 (d, J = 7.9 Hz), 129.46 (d, J = 3.5 Hz), 131.74, 153.73,
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157.33 (d, J = 246.2 Hz), 176.11. Anal. Calcd for C11H10BrFN2O2: C, 43.88; H, 3.35; N, 9.30.
Found: C, 43.69; H, 3.48; N, 9.33.
3-(4-Fluoro-3-(methylsulfonyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione (15). Step 1. To
a solution of triphosgene (517 mg, 1.7 mmol) in toluene (10 mL) at 0 °C was added slowly a
solution of 4-fluoro-3-(methylsulfonyl)aniline (54) (825 mg, 4.36 mmol) in EA (10 mL). The
reaction mixture was then heated to 80 °C for 16 h. The reaction was cooled to rt and the solvent
was removed in vacuo to afford the corresponding isocyanate as a white solid which was
dissolved in CH3CN (10 mL). This solution was added dropwise to a stirring solution of 58 (675
mg, 6.5 mmol) in 1 M NaOH (15 mL) at 0 °C. After stirring at rt for 16 h, the reaction mixture
was concentrated and the aq. layer washed with EA (30 mL). The aq. layer was then concentrated
and the pH was adjusted to 1 with conc. HCl. After cooling in an ice bath, 15 (242 mg, 18%)
precipitated as a tan solid which was filtered, washed with H2O (2 x 20 mL) and dried. mp 209–
211 oC. 1H NMR (500 MHz, DMSO-d6) δ 1.42 (s, 6H), 3.38 (s, 3H), 7.67 (t, J = 9.4 Hz, 1H), 7.86
(ddd, J = 2.7, 4.5, 8.8 Hz, 1H), 7.98 (dd, J = 2.6, 6.3 Hz, 1H), 8.67 (s, 1H). 13C NMR (125 MHz,
DMSO-d6) δ 24.62, 43.61, 43.63, 57.96, 117.88 (d, J = 22.9 Hz), 127.11, 128.49 (d, J = 16.5 Hz),
128.92 (d, J = 3.4 Hz), 134.53, 134.60, 153.61, 156.32, 158.35, 176.08. HRMS (EI-Ion trap) m/z:
[M+] Calcd for C12H14FN2O4S 301.0653, found 301.0631.
3-(3-(1,1-Difluoropropyl)-4-fluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (17). Step 1.
1-(2-fluorophenyl)propan-1-one (48) (1.068 g, 7.0 mmol) was added dropwise to fuming HNO3
(20 mL) at -45 oC and the mixture was stirred at -45 oC for 1.5 h. The mixture was transferred to
an ice bath and water (50 mL) was added in portions over 10 min and the mixture was stirred for
2 h. The precipitate was filtered and washed with water (100 mL) and dried in vacuo to afford 1(2-fluoro-5-nitrophenyl)propan-1-one (49) (1.384 g, 100%) as a white solid. 1H NMR (500 MHz,
CDCl3) δ 1.24 (t, J = 7.1 Hz, 3H), 3.05 (qd, J = 3.2, 7.1 Hz, 2H), 7.34 (t, J = 9.3 Hz, 1H), 8.40
(dt, J = 3.5, 8.9 Hz, 1H), 8.77 (dd, J = 2.9, 6.0 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 7.83 (d, J
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= 2.0 Hz), 36.92 (d, J = 7.2 Hz), 118.26 (d, J = 26.8 Hz), 126.48 (d, J = 16.3 Hz), 126.88 (d, J =
5.0 Hz), 129.11 (d, J = 11.1 Hz), 144.53, 164.75 (d, J = 264.3 Hz), 196.65 (d, J = 4.8 Hz). Step 2.
To a pressure vessel was added 49 (4.518 g, 22.9 mmol) to neat Deoxo-Fluor (5.222 g, 23.6
mmol) with stirring at rt. The vessel was sealed and the mixture was heated to 85 oC for 24 h. The
mixture was cooled to rt and water (30 mL) was added and the organic layer was separated. The
aq. layer was washed with DCM (2 x 20 mL) and the combined organic layers were washed with
brine and dried with Na2SO4. Solvent was removed in vacuo to afford 2-(1,1-difluoropropyl)-1fluoro-4-nitrobenzene (50) (5.422 g, 100%) as a red oil which was used in the next step without
purification. 1H NMR (400 MHz, CDCl3) δ 1.03 (t, J = 7.5 Hz, 3H), 2.20 – 2.40 (m, 2H), 7.30
(dd, J = 8.5, 17.7 Hz, 1H), 8.35 (dt, J = 3.5, 8.9 Hz, 1H), 8.46 (dd, J = 2.8, 6.2 Hz, 1H). Step 3.
To a stirring solution of 50 (5.422 g, 24.7 mmol) dissolved in conc. HCl (10 mL), MeOH (25
mL), and H2O (10 mL), was added Fe powder (4.6 g, 82.4 mmol) in portions over 10 min at rt.
After effervescence ceased, the reaction mixture was stirred for an additional 24 h before
basification with Na2CO3 to pH 10. DCM was then added and the mixture was stirred for 10 min
and filtered through Celite. The organic layer was separated and washed with brine and dried with
MgSO4. The solvent was removed in vacuo and the crude residue was purified by sg
chromatography (hexane to EA/hexane 1:1) to afford 3-(1,1-difluoropropyl)-4-fluoroaniline (51)
(1.696 g, 36%) as a yellow oil which was not further purified. 1H NMR (400 MHz, CDCl3) δ 0.98
(t, J = 7.5 Hz, 3H), 2.10 – 2.37 (m, 2H), 3.62 (s, 2H), 6.60 – 6.71 (m, 1H), 6.79 (dd, J = 3.0, 6.1
Hz, 1H), 6.84 – 6.96 (m, 1H). Step 4. Following the method of Leas et al. (2017), 51 (4.377 g,
23.1 mmol), NaNO2 (7.216 g, 104.6 mmol), CH2I2 (7.465 g, 27.8 mmol), water (25 mL), and
DCM (25 mL) were stirred for 10 min at rt. Glacial AcOH was then added in one portion (13 mL)
and the reaction was stirred for 1 h before separation of the organic layer. The aq. layer was
extracted with DCM (3 x 30 mL) and the combined organic layers were washed with brine, dried
over MgSO4, and concentrated in vacuo to give an oil which was purified by sg chromatography
(hexane) to afford 2-(1,1-difluoropropyl)-1-fluoro-4-iodobenzene (52) (4.6 g, 66%) as a yellow
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oil. 1H NMR (400 MHz, CDCl3) δ 0.99 (t, J = 7.5 Hz, 3H), 2.12 – 2.34 (m, 2H), 6.80 – 7.07 (m,
1H), 7.68 – 7.74 (m, 1H), 7.81 (dd, J = 2.2, 6.9 Hz, 1H). Step 5. A stirred solution of 52 (4.6 g,
15.3 mmol), 33 (2.249 g, 17.55 mmol), Cu2O (1.089 g, 8.5 mmol), and DMA (10 mL) was sealed
in a pressure vessel and heated to 160 oC for 24 h. After cooling to rt, the solvent was removed in
vacuo to afford a residue which was purified by sg chromatography (hexane to hexane/EA 1:1)
gave a solid which was recrystallized (Et2O/hexane 1:10) to afford 17 (620 mg, 13%) as a white
microcrystalline solid. mp 85–87 oC. 1H NMR (500 MHz, DMSO) δ 0.94 (t, J = 7.4 Hz, 3H), 1.41
(s, 6H), 2.27 (tq, J = 7.3, 15.2 Hz, 2H), 7.48 (t, J = 9.9 Hz, 1H), 7.56 – 7.69 (m, 2H), 8.61 (s, 1H).
C NMR (125 MHz, DMSO) δ 6.54 (t, J = 4.9 Hz), 24.66, 30.42 (t, J = 27.6 Hz), 57.86, 117.13
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(d, J = 23.3 Hz), 121.85 (td, J = 2.6, 242.2 Hz), 123.55 (td, J = 13.6, 27.8 Hz), 125.56 (td, J = 3.0,
8.2 Hz), 128.53 (d, J = 3.2 Hz), 130.87 (d, J = 9.1 Hz), 153.88, 157.50 (d, J = 251.0 Hz), 176.22.
Anal. Calcd for C14H15F3N2O2: C, 56.00; H, 5.04; N, 9.33. Found: C, 55.98; H, 5.29; N, 9.58.
3-(4-Fluoro-3-(2,2,2-trifluoroethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione (18). Step 1.
To a stirred solution of 1-fluoro-4-nitro-2-(2,2,2-trifluoroethyl)benzene (1.7 g, 7.6 mmol) in
EtOH (20 mL) was added 10% Pd/C (200 mg) and (NH4)2CO3 (4.277 g, 6.8 mmol). The mixture
was sealed with a balloon and heated to 80 oC for 24 h. After solvent removal in vacuo, the
residue was dissolved in EA (20 mL) and washed with H2O (20 mL). The aq. layer was extracted
with EA (3 x 20 mL) and the organic layers were combined and washed with brine (40 mL) and
dried with MgSO4. The solvent was removed in vacuo to afford 4-fluoro-3-(2,2,2trifluoroethyl)aniline (55) (1.310 g, 89%) as an orange oil which was used in the next step
without further purification. 1H NMR (400 MHz, CDCl3) δ 3.35 (q, J = 10.6 Hz, 2H), 3.58 (s,
2H), 6.57 – 6.65 (m, 2H), 6.89 (t, J = 9.4 Hz, 1H). Step 2. To a solution of triphosgene (1.006 g,
3.4 mmol) in toluene (10 mL) at 0 °C was slowly added a solution of 55 (1.310 g, 6.8 mmol) in
EA (10 mL). The reaction mixture was then heated to 80 °C for 24 h. The reaction was cooled to
rt and the solvent was removed in vacuo to afford the corresponding isocyanate as a yellow oil
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which was dissolved in CH3CN (10 mL). This solution was added dropwise to a stirred solution
of 58 (1.2 g, 11.6 mmol) in 1 M NaOH (20 mL) at 0 °C. After stirring at rt for 16 h, the reaction
mixture was concentrated and the aq. layer washed with EA (30 mL). The aq. layer was then
concentrated and the pH was adjusted to 1 with 10% HCl, followed by heating to reflux for 1 h.
The mixture was cooled and the resulting precipitate was filtered and washed with H2O (2 x 20
mL) to afford 18 (856 mg, 41%) as a white solid. mp 153–155 oC. 1H NMR (400 MHz, DMSO) δ
1.39 (s, 6H), 3.74 (q, J = 11.2 Hz, 2H), 7.38 (t, J = 9.1 Hz, 1H), 7.41 – 7.47 (m, 1H), 7.49 (dd, J =
2.4, 6.6 Hz, 1H), 8.61 (s, 1H). 13C NMR (125 MHz, DMSO) δ 24.79, 32.22 (d, J = 31.0 Hz),
57.99, 115.95, 116.04 (d, J = 23.7 Hz), 117.96 (d, J = 14.3 Hz), 128.13 (q, J = 280.8 Hz), 128.51
(d, J = 3.2 Hz), 129.29 (d, J = 9.0 Hz), 131.16 (d, J = 4.1 Hz), 154.12, 159.93 (d, J = 246.7 Hz),
176.49. Anal. Calcd for C13H12F4N2O2: C, 51.32; H, 3.98; N, 9.21. Found: C, 51.50; H, 4.09; N,
9.19.
3-(4-Fluoro-3-(trifluoromethoxy)phenyl)-5,5-dimethylimidazolidine-2,4-dione (19). A
stirring solution of 2-fluoro-5-bromo-trifluoromethoxybenzene (28) (1.728 g, 6.7 mmol), 33
(1.123 g, 8.8 mmol), Cu2O (617 mg, 4.3 mmol), and DMA (10 mL) was sealed in a pressure
vessel and heated to 160 oC for 24 h. The solvent was removed in vacuo to afford a residue which
was purified by sg chromatography (hexane to hexane/EA 1:1) to afford a pale yellow solid
which was recrystallized (Et2O/hexane 1:5) to give 19 (1.47 g, 72%) as a white microcrystalline
solid. mp 109–110 oC. 1H NMR (500 MHz, DMSO) δ 1.41 (s, 6H), 7.54 (dq, J = 2.6, 3.1, 9.0 Hz,
1H), 7.64 (t, J = 9.6 Hz, 1H), 7.71 (d, J = 7.1 Hz, 1H), 8.65 (s, 1H). 13C NMR (125 MHz, DMSO)
δ 24.62, 57.86, 117.49 (d, J = 19.6 Hz), 119.99 (q, J = 257.2 Hz), 122.52, 127.87 (d, J = 7.6 Hz),
129.12 (d, J = 3.5 Hz), 134.70 (dd, J = 13.5, 2.0 Hz), 152.59 (d, J = 249.9 Hz), 153.64, 176.05.
Anal. Calcd for C12H10F4N2O3: C, 47.07; H, 3.29; N, 9.15. Found: C, 47.13; H, 3.42; N, 9.13.
5,5-Dimethyl-3-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)imidazolidine-2,4-dione (20). Step
1. Following the method of Leas et al. (2017), to a stirred solution of 2-methyl-6-
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(trifluoromethyl)pyridin-4-amine (Arigiriadi et al., 2016) (880 mg, 5 mmol) in DCM (10 mL)
and H2O (10 mL) was added CH2I2 (2.033 g, 7.6 mmol) and NaNO2 (1.724 g, 25 mmol). After 10
min, AcOH (5 mL) was added and the solution was sealed with a balloon and stirred for 16 h.
The organic layer was separated and the aq. layer extracted with DCM (2 x 20 mL). The
combined organic layers were washed with brine (30 mL) and dried over MgSO4 to give 4-iodo2-methyl-6-(trifluoromethyl)pyridine (31) (905 mg, 63%) as a red oil that was used in the next
step without further purification. 1H NMR (400 MHz, CDCl3) δ 2.58 (s, 3H), 7.79 (s, 1H), 7.86 (s,
1H). Step 2. A stirred mixture of 31 (905 mg, 3.2 mmol), 33 (693 mg, 5.4 mmol), Cu2O (350 mg,
2.4 mmol), and DMA (10 mL) in a pressure vessel was heated to 180 oC for 24 h. After solvent
removal in vacuo, the residue was purified with sg chromatography (hexane to hexane/EtOAc
1:1) which gave a crude solid which was recrystallized (Et2O/hexane 1:5) to give 20 (170 mg,
19%) as a white microcrystalline solid. mp 160–162 oC. 1H NMR (400 MHz, DMSO) δ 1.42 (s,
6H), 2.60 (s, 3H), 7.79 (d, J = 1.6 Hz, 1H), 7.92 (d, J = 1.7 Hz, 1H), 8.86 (s, 1H). 13C NMR (150
MHz, DMSO) δ 23.98, 24.63, 57.86, 113.88 (q, J = 3.2 Hz), 121.40 (q, J = 274.1 Hz), 121.95,
141.78, 146.33 (q, J = 33.8 Hz), 152.78, 160.40, 175.74. Anal. Calcd for C12H12F3N3O2: C, 50.18;
H, 4.21; N, 14.63. Found: C, 50.20; H, 4.17; N, 14.58.
5,5-Dimethyl-3-(6-(trifluoromethyl)pyridin-2-yl)imidazolidine-2,4-dione (21). Step 1. 6(trifluoromethyl)pyridin-2-amine (1.01 g, 6.2 mmol), NaNO2 (2.170 g, 31.4 mmol), CH2I2 (3.221
g, 12.0 mmol), water (5 mL), and CH2Cl2 (5 mL) were stirred for 10 min at rt. AcOH was then
added in one portion (7.4 g, 123.3 mmol) and the reaction was stirred for 1 h. After removal of
the organic layer, the aq. layer was extracted with DCM (3 x 20 mL). The combined organic
layers were washed with brine, dried over MgSO4, and concentrated in vacuo to afford 2-iodo-6(trifluoromethyl)pyridine (30) (1.00 g, 59%) as a yellow solid which was used in the next step.
Step 2. To a solution of 33 (903 mg, 7.0 mmol) and Cu2O (355 mg, 2.5 mmol) in DMA (25 mL)
was added 30 (1.00 g, 3.7 mmol) in a pressure flask. The vessel was sealed and the mixture
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heated to 150 oC for 48 h. After cooling to rt, the solvent was evaporated in vacuo. The residue
was purified by sg chromatography (hexane to EA) and recrystallized (H2O/EtOH 1:1) to afford
21 (400 mg, 40%) as a white microcrystalline solid. mp 212–214 oC. 1H NMR (400 MHz,
DMSO) δ 1.44 (s, 6H), 7.82 (d, J = 8.0 Hz, 1H), 8.01 (d, J = 7.7 Hz, 1H), 8.30 (t, J = 7.9 Hz, 1H),
8.72 (s, 1H). 13C NMR (125 MHz, DMSO) δ 24.69, 58.25, 120.83 (d, J = 3.1 Hz), 121.14 (d, J =
273.0 Hz), 126.52, 141.16, 149.99 (q, J = 34.4 Hz), 146.38, 153.08, 175.67. Anal. Calcd for
C11H10F3N3O2: C, 48.36; H, 3.69; N, 15.38. Found: C, 48.53; H, 3.82; N, 15.50.
3-(2,4-Difluoro-3-(trifluoromethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione (22). Step 1.
To a stirred solution of 10% Pd/C (367 mg) was added 1,3-difluoro-4-nitro-2(trifluoromethyl)benzene (5.00 g, 22.0 mmol). The reaction vessel was evacuated and sparged
with H2 gas and sealed with a H2 balloon for 4 d. The reaction mixture was then filtered through
Celite and concentrated in vacuo to afford 2,4-difluoro-3-(trifluoromethyl)aniline (56)
(Wollweber and Brandes, 1989) (2.00 g, 46%) as a an orange oil that was used in the next step
without further purification. 1H NMR (400 MHz, CDCl3) δ 3.21 (s, 2H), 6.81 (t, J = 9.6 Hz, 1H),
6.89 (td, J = 5.1, 9.1 Hz, 1H). Step 2. To a solution of triphosgene (2.354 g, 7.9 mmol) in toluene
(20 mL) at rt was slowly added a solution of 56 ( 2.00 g, 10.1 mmol) in EA (10 mL). The
reaction mixture was then heated to 80 oC for 16 h. After cooling to rt, the solvent was removed
in vacuo to afford the corresponding isocyanate as a yellow semi-solid which was dissolved in
CH3CN (10 mL). This solution was added dropwise to a stirred solution of 58 (1.374 g, 13.3
mmol) in 1 M NaOH (20 mL) at 0 °C. After the reaction mixture was stirred at rt for 16 h, it was
concentrated in vacuo and the aq. layer washed with EA (30 mL). The aq. layer was then
concentrated and the pH was adjusted to 1 with concentrated HCl. After cooling to 0 °C, the
precipitate was filtered and washed with H2O (2 x 20 mL) to give 2-(3-(2,4-difluoro-3(trifluoromethyl)phenyl)ureido)-2-methylpropanoic acid (3.0 g, 91%) as a white crystalline solid
which was used to the next step without further purification. 1H NMR (500 MHz, DMSO) δ 1.42

83
(s, 6H), 7.03 (s, 1H), 7.26 (t, J = 10.1 Hz, 1H), 8.36 (td, J = 5.7, 9.1 Hz, 1H), 8.56 (d, J = 2.5 Hz,
1H), 12.42 (s, 1H). Step 3. To a pressure vessel was added 10% HCl (15 mL) and 2-(3-(2,4difluoro-3-(trifluoromethyl)phenyl)ureido)-2-methylpropanoic acid (500 mg, 1.5 mmol) with
stirring. The vessel was sealed and heated to 100 oC for 3 d. The solution was cooled to rt. After
filtration, a H2O wash (3 x 20 mL) and drying, 22 (470 mg, 99%) was isolated as a white solid.
mp 156–158 oC. 1H NMR (400 MHz, DMSO) δ 1.43 (s, 6H), 7.59 (t, J = 10.4 Hz, 1H), 7.98 (td, J
= 5.6, 8.6 Hz, 1H), 8.79 (s, 1H). 13C NMR (150 MHz, DMSO) δ 24.32, 24.97, 58.67, 106.82 (m),
113.87 (dd, J = 23.0, 4.0 Hz), 117.54 (dd, J = 13.1, 3.5 Hz), 121.27 (q, J = 272.28 Hz), 136.47 (d,
J = 10.8 Hz), 152.87, 153.63 (d, J = 3.8 Hz), 155.38 (d, J = 2.7 Hz), 157.76 (d, J = 1.9 Hz),
159.48 (d, J = 0.1 Hz), 175.77. Anal. Calcd for C12H9F5N2O2: C, 46.76; H, 2.94; N, 9.09. Found:
C, 46.61; H, 3.03; N, 9.37.
3-(3-Chloro-4-fluoro-5-(trifluoromethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione (23).
Step 1. 3-Chloro-4-fluoro-5-(trifluoromethyl)aniline (1.651 g, 7.7 mmol), NaNO2 (2.910 g, 42.2
mmol), CH2I2 (3.202 g, 12.0 mmol), H2O (10 mL), and DCM (10 mL) were stirred for 10 min at
rt. AcOH (9.3 g, 154.9 mmol) was then added in one portion and the reaction mixture was stirred
for 1 h. After removal of the organic layer, the aq. layer was extracted with DCM (3 x 20 mL).
The combined organic layers were washed with brine, dried over MgSO4, and concentrated in
vacuo to afford crude 1-chloro-2-fluoro-5-iodo-3-(trifluoromethyl)benzene (32) (2.50 g, 100%) as
a yellow oil which was used in the next step. Step 2. To a mixture of 33 (1.090 g, 8.5 mmol) and
Cu2O (553 mg, 3.9 mmol) in DMA (10 mL) was added 32 (2.50 g, 7.7 mmol) in a pressure flask.
The flask was sealed and the mixture heated to 170 oC for 48 h and then cooled to rt. After
solvent removal in vacuo, the residue was purified by sg chromatography (hexane to EA) and
recrystallized (Et2O/hexane 1:5) to afford 23 (600 mg, 24%) as a white crystalline solid. mp 161–
162 oC. 1H NMR (600 MHz, DMSO) δ 1.42 (s, 6H), 7.94 (dd, J = 2.5, 5.9 Hz, 1H), 8.12 (dd, J =
2.4, 6.4 Hz, 1H), 8.72 (s, 1H). 13C NMR (150 MHz, DMSO) δ 24.55, 58.06, 117.65 – 118.00 (m),
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121.41 (d, J = 17.8 Hz), 121.75 (d, J = 272.9 Hz), 124.63 (q, J = 4.7 Hz), 129.42 (d, J = 4.4 Hz),
133.39, 153.24 (d, J = 256.8 Hz), 153.34, 175.85. Anal. Calcd for C12H9ClF4N2O2: C, 44.39; H,
2.79; N, 8.63. Found: C, 44.00; H, 2.79; N, 8.47.
2-(4,4-Dimethyl-2,5-dioxoimidazolidin-1-yl)-5-fluoro-4-(trifluoromethyl)benzonitrile (24).
Step 1. A mixture of tert-butyl 2-(3-(4-fluoro-2-iodo-5-(trifluoromethyl)phenyl)ureido)-2methylpropanoate (59) (Wu et al., BMCL 2018 UC) (490 mg, 1.00 mmol), CuI (38 mg, 0.20
mmol) and 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU) (419 mg, 2.75 mmol) in DMSO (4 mL) in
a sealed vial was irradiated for 20 min at 120 °C. The reaction mixture was cooled to rt and then
partitioned between EA (40 mL) and 1N HCl (20 mL). The organic layer was washed with brine,
dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was purified by sg
flash column chromatography (hexane/EA 4:1) to afford 3-(4-fluoro-2-iodo-5(trifluoromethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione (60) (235 mg, 56%) as a white
solid. mp 192–193 oC. 1H NMR (500 MHz, CDCl3) δ 1.58 (d, J = 4.4 Hz, 3H), 1.64 (d, J = 3.9
Hz, 3H), 6.03 (s, 0.4H), 6.47 (s, 0.6H), 7.50 (d, J = 6.4 Hz, 1H), 7.82 (d, J = 8.9 Hz, 1H). 13C
NMR (125 MHz, CDCl3) δ 24.92, 25.43, 59.75, 104.09 (d, J = 8.2 Hz), 119.81 (qd, J = 33.9, 13.8
Hz), 120.35 (d, J = 272.9 Hz), 128.07 (q, J = 2.8 Hz), 128.53, 128.72, 131.09 (d, J = 3.9 Hz),
154.19, 158.88 (d, J = 264.9 Hz), 175.12. Anal. Calcd for C12H9F4IN2O2: C, 34.64; H, 2.18; N,
6.73. Found: C, 34.42; H, 2.02; N, 6.97. Step 2. A mixture of 60 (416 mg, 1.00 mmol), copper(I)
cyanide (180 mg, 2.00 mmol) and DMF (5 mL) in a sealed tube was stirred at 120 °C for 16 h
under Ar. The solid was filtered and washed with EA, and the filtrate was partitioned in EA (50
mL) and H2O (20 mL). The organic layer was separated and washed with brine, dried over
anhydrous MgSO4, filtered and concentrated in vacuo. The residue was purified by sg
chromatography (hexane/EA 1:1) to afford 24 (190 mg, 60%) as a white solid. mp 206–207 °C.
H NMR (500 MHz, DMSO-d6) δ 1.46 (s, 6H), 8.31 (d, J = 6.5 Hz, 1H), 8.45 (d, J = 10.0 Hz,

1

1H), 8.90 (s, 1H). 13C NMR (125 MHz, DMSO) δ 24.94, 59.19, 114.03, 118.16 (d, J = 11.0 Hz),
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121.82 (q, J = 273.4 Hz), 122.17 (qd, J = 33.9, 13.8 Hz), 123.26, 123.47, 129.97 (q, J = 4.2 Hz),
131.80 (d, J = 3.8 Hz), 153.10, 158.38 (d, J = 259.1 Hz), 175.96. Anal. Calcd for C13H9F4N3O2:
C, 49.53; H, 2.88; N, 13.33. Found: C, 49.73; H, 2.96; N, 13.51.
5,5-Dimethyl-3-(3-(pentafluoro-λ6-sulfaneyl)phenyl)imidazolidine-2,4-dione (25). Step 1.
Following the method of Leas et al. (2017), 3-(pentafluoro-λ6-sulfaneyl)aniline (586 mg, 2.7
mmol), NaNO2 (926 mg, 13.0 mmol), CH2I2 (1.438 g, 5.4 mmol), water (5 mL), and DCM (5 mL)
were stirred for 5 min at rt. AcOH was then added in one portion (3.076 g, 51.2 mmol) and the
reaction was stirred for 24 h. The organic layer separated and the aq. layer was extracted with
DCM (3 x 20 mL). The combined organic layers were washed with brine, dried over MgSO4, and
concentrated in vacuo to afford pentafluoro-(3-iodophenyl)-λ6-sulfane (29) (314 mg, 35%) as a
yellow gel which was used for the next step without further purification. 1H NMR (400 MHz,
CDCl3) δ 7.20 (t, J = 10 Hz, 1H), 7.73 (ddd, J = 0.9, 2.3, 8.3 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H),
8.08 (t, J = 1.9 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 93.29, 125.39 (quintet, J = 4.8 Hz),
130.44, 134.87 (quintet, J = 4.7 Hz), 140.82, 154.67 (quintet, J = 17.4 Hz). Step 2. A mixture of
29 (314 mg, 0.95 mmol), 33 (183 mg, 1.8 mmol) and Cu2O (110 mg, 0.78 mmol) in DMA (12.5
mL) was stirred at 150 oC for 48 h. The solvent was removed in vacuo and the residue was
purified by sg chromatography (hexane to EA/hexane 1:1) to afford 25 (88 mg, 28%) as a pale
yellow microcrystalline solid. mp 126–128 °C. 1H NMR (500 MHz, DMSO-d6) δ 1.41 (s, 6H),
7.72 (m, 2H), 7.88 – 7.96 (m, 1H), 8.02 (s, 1H), 8.66 (s, 1H). 13C NMR (500 MHZ, DMSO-d6) δ
24.54, 57.85, 124.06, 124.10, 129.58, 130.61, 132.82, 152.38 (t, J = 16.6 Hz), 153.54, 175.98.
Anal. Calcd for C11H11F5N2O2S: C, 40.00; H, 3.36; N, 8.48. Found: C, 39.96; H, 3.25; N, 8.55.
3-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-5,5-dimethylimidazolidine-2,4-dione (26). To a
stirred solution of 58 (1.072 g, 10.4 mmol) in 1 M NaOH (20 mL) at 0 °C, was added dropwise
2,2-difluoro-5-isocyanatobenzo[d][1,3]dioxole (Wu et al., BMCL 2018 U) (1.37 g, 6.9 mmol) in
CH3CN (10 mL). After stirring at rt for 16 h, the reaction mixture was concentrated in vacuo and
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the aq. layer washed with EA (30 mL). The aq. layer was then concentrated and the pH was
adjusted to 1 with 10% HCl, followed by heating to reflux for 24 h. The mixture was cooled and
the resulting precipitate was filtered and washed with H2O (2 x 20 mL) to give 26 (588 mg, 30%)
as a tan solid. mp 151–153 oC. 1H NMR (400 MHz, DMSO) δ 1.40 (s, 6H), 7.24 (dd, J = 2.0, 8.6
Hz, 1H), 7.52 (d, J = 4.1 Hz, 1H), 7.53 (d, J = 2.4 Hz, 1H), 8.61 (s, 1H). 13C NMR (125 MHz,
DMSO) δ 24.67, 57.86, 109.72, 109.97, 123.59, 128.34, 131.31 (t, J = 252.5 Hz), 141.91, 142.43,
153.89, 176.24. Anal. Calcd for C12H10F2N2O4: C, 50.71; H, 3.55; N, 9.86. Found: C, 50.92; H,
3.66; N, 10.02.
3-(4-Fluoro-3-(trifluoromethyl)phenyl)-5-methyl-5-(trifluoromethyl)imidazolidine-2,4-dione
(28). To a stirred solution of 44 (2.033 g, 11.2 mmol) and Cu2O (731 mg, 5.1 mmol) in DMA (10
mL) was added 4-bromo-2-(1,1-difluoroethyl)-1-fluorobenzene (47) (1.00 g, 4.2 mmol). The
reaction vessel was sealed and the mixture heated to 170 oC for 24 h. After cooling to rt, the
solvent was evaporated in vacuo and the residue was purified by sg chromatography (hexane to
1:1 EA:hexane) and recrystallized (ether/hexane 1:10) to afford 28 (407 mg, 29%) as a yellow
crystalline solid. mp 120–122 oC. 1H NMR (500 MHz, DMSO) δ 1.71 (s, 3H), 2.03 (t, J = 19.2
Hz, 3H), 7.53 (t, J = 9.7 Hz, 1H), 7.57 – 7.63 (m, 1H), 7.65 (dd, J = 2.0, 6.8 Hz, 1H), 9.63 (s,
1H). 13C NMR (125 MHz, DMSO) δ 16.32, 24.60 (td, J = 2.8, 27.8 Hz), 62.61 (q, J = 29.2 Hz),
117.61 (d, J = 23.3 Hz), 120.21 (t, J = 240.8 Hz), 123.47 (q, J = 284.3 Hz), 124.84 (dd, J = 13.7,
27.8 Hz), 125.07 – 125.59 (m), 127.47 (d, J = 3.1 Hz), 131.16 (d, J = 9.4 Hz), 154.29, 158.14 (d,
J = 252.2 Hz), 167.93. Anal. Calcd for C13H10F6N2O2: C, 45.89; H, 2.96; N, 8.23. Found: C,
46.03; H, 3.00; N, 8.45.
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Chapter 4: Summary
One of the most prevalent tropical infectious diseases is Schistosomiasis, which is caused
by trematode fluke’s with life cycles involving invertebrate and vertebrate hosts as well as freeswimming stages (Aragon et al., 2009; McManus et al., 2013). The burden of the disease is
attributable to the three major human schistosome species (S. mansoni, S. Haematobium, and S.
japonicum), and 220.8 million people required preventive treatment for schistosomiasis in 2017
according to the World Health Organization (WHO). In the absence of vaccines and with the
challenges surrounding implementation of other preventive measures such as access to safe water
and improved sanitation, the current and precarious mainstay for management and treatment of
schistosomiasis is praziquantel (PZQ) (Loukas et al.; 2013). This dependence on a single drug is
disturbing because recent studies have revealed emerging evidence of drug resistant
schistosomes. Melman et al. (2009) discovered S. mansoni isolates collected from several
individuals from Kisumu, Kenya, were less susceptible to PZQ in contrast to samples collected
from other sources further suggesting natural selection for worms with less susceptibility is
potentially rising. It is also worth noting that schistosomes exposed to repeated in vivo PZQ
treatments have reduced drug sensitivities (Pica-Mattoccia et al., 2009). While being active
toward adult schistosomes, PZQ is inactive against juvenile flukes further decreasing its viability
as a broad spectrum anthelmintic (Hotez et al., 2010; Utzinger et al., 2000) and until recently,
drug discovery for schistosomiasis had languished (Horton at al., 2003; Caffery et al., 2011).
Exploiting the Hoffmann La-Roche Ro 13-3978 scaffold as a starting point, Wang et al.
(2016) developed several libraries of structurally diverse analogs of Ro 13-3978. While numerous
compounds identified exhibited good antischistosomal activity and lower antiandrogenic effects
compared to Ro 13-3978, the desired potency was not achieved and a clear correlation between
good activity/low side effects and compound structural features was indistinct. The overall goal
of this research was to use the investigation conducted by Hoffmann La-Roche and Wang et al.
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(2016) as a “foot in the door,” such that a novel next-generation hydantoin chemical series could
be developed in order to identify analogs with superior antischistosomal efficacy, selectivity, and
optimized absorption-distribution-metabolism-excretion (ADME) profiles.
In chapter 2, I described a new chemical reaction that was developed in order to
circumvent the problem of the unavailability of some aryl halide starting materials from
commercial sources. These specific aryl halides were necessary for the synthesis of target aryl
hydantoins and various intermediates. The reaction uses mild one-pot conditions to elicit halogen
abstraction from bromotrichloromethane or diiodomethane via an SRN1-like mechanism to yield
desired anilines and provides a convenient alternative to the classic Sandmeyer reaction.
Chapter 3 describes the synthesis of several aryl hydantoin analogues herein. These
compounds were prepared in an effort to probe the structure–activity relationship around the
phenyl substituent and hydantoin core for the studies toward antischistosomal activity.
Compounds 27 and 28 were identified as potential single-dose aryl hydantoin drug development
candidates with 27 being the main frontrunner.
We have now completed optimization of this compound series and identified 27 as a first
drug development candidate with five backup compounds. As shown in Table 4.1, the
physicochemical and in vitro ADME properties of these compounds including LogD7.4 values of
2.7–3.5, aqueous kinetic solubilities of 25 to >100 μg/mL, estimated plasma protein binding
(cPPB) values of 33–92%, and human (h) and mouse (m) microsomal in vitro CLint values
ranging from <7 to 8 μL/min/mg protein are associated with excellent pharmacokinetic profiles
(see 100 mg/kg po Cmax and AUC0–last data). 27 embodies the two key advances in our
optimization of Ro 13-3978–replacing the hydrogen atoms of the gem–dimethyl substructure with
deuteriums to slow Phase I metabolism and swapping the trifluoromethyl substituent
with a difluoroethyl to abolish antiandrogenic effects (LAPC4 IC50 >100 μM).
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Table 4.1. Drug candidate activity and physiochemical results
Compd

gLogD7.4 Sol2.0/Sol6.5
(μg/mL)

h/m CLint
Cmax
(μL/min/mg (μg/mL)
protein)

AUC0-last
(μg/mL/h)

LAPC4
IC50
(μM)

Ro 133978
10

2.7

>100/>100

8/<7

36

795

11

S.
Mansoni
A/J ED50
(mg/kg)
15/140

3.5

<7/<7

28

966

5.2

14/70

12
16
9

2.7
2.6
3.2

<7/<7
7/<7
<7/<7

43
40
42

1815
1561
1646

13
>100
4.2

7.3/73
20/23
9.0/88

27
28

2.5
3.4

2550/25-50
>100/>100
>100/>100
50-100/50100
>100/>100
50-100/50100

<7/<7
<7/<7

41
34

1799
1286

>100
2.9

7.1/16
1.2/89
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The superior pharmacokinetic properties of 27 translated into substantially better
antischistosomal efficacy than Ro 13-3978–single oral dose ED50 values of 7.1 and 16 mg/kg
against adult (A) and juvenile (J) S. mansoni in a mouse model. 27 at a single 50 mg/kg oral dose
also completely cleared S. haematobium infections in hamsters (data not shown). Lastly, 27 is
promising because it is obtained from inexpensive starting materials using an operationally
simple five-step synthesis.
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Appendix A: Proof of publishers permission
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Appendix B: Supplemental information for the one-pot, metal-free conversion of anilines to
aryl bromides and iodides, chapter 2

Scheme B1. Exchange Reaction for Calculating relative G for Diazonium Bond
Cleavage

(Δ G°exchange = ΔGoproducts - ΔG°reactants, Δ G°exchange/-1.36 kcal/mol = log (KR/KH))
Hammet plot calculations
Exchange reaction:

ΔGexchange= ΔGo = ∑ 𝑛ΔGproducts – ∑ 𝑛ΔGreactants
(1)
Hammet equation: log

KX
KH

= σρ

(2)
K

log K X = logK X − logK H
H

(3)
ΔG=-RTln(K) = -2.303RTlog(K) so
ΔGx
ΔGH
− 2.303RT
2.303RT

ΔGo

ΔG
−2.303RT
K

= − 2.303RT = log K X

H

= logK, pluging this into eqn. 3 gives expression 4
R = 0.00198588 Kcal/mol·K, T = 298.15 K

(4)
K

log K x =
H

ΔGexchange
−1.36

, therefore a plot of Hammet σ values vs

ΔG𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒
−1.36

generates the slope ρ.

Computational methods and calculations
Structures were built in Gaussview 5.0 and initially optimized with MM2 molecular mechanics
minimization. The aryl diazoniums were modeled as single cations, i.e. charge: 1, spin: singlet.

102
Aryl radicals were modeled using charge: 0, and spin: doublet. The resulting configurations were
chosen as starting geometries for DFT free energy calculations using Gaussian 09 software
(Frisch et al., 2009, Gaussian, Wallingford, CT, USA). Geometry optimization and thermal
corrections to the free energy were then calculated using the UB3LYP/6-31+G(d) functional and
basis set with dichloromethane solvation effects using the polarizable continuum model (PCM) .
The electronic energies were further refined using the 6-311++G(2d,p) basis set, again with the
UB3LYP functional with solvation effects accounted for by the PCM model in dichloromethane.
The modeling nomenclature for this method is: UB3LYP/6-311++G(2d,p)// UB3LYP/6-31+G(d),
PCM = dichloromethane (Stack et al., 2015).
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Table B1. Summary of free energy calculations

Phradical
Phdiazonium
CH3Phradical
CH3Phdiazonium
MeOPhradical
MeOPhdiazonium
FPhradical
FPhdiazonium
CNPhradical
CNPhdiazonium
NO2Phradical
NO2Phdiazonium
COOHPhradical
COOHPhdiazonium
CONH2Phradical
CONH2Phdiazoniu
m
NH2SO2Phradical
NH2SO2Phdiazoniu
m
CF3Phradical
CF3Phdiazonium
CHOPhradical
CHOPhdiazonium
AcetylPhradical
AcetylPhdiazonium

thermo correction
0.05932
0.069041
0.082434
0.092625
0.088279
0.097972
0.049713
0.059421
0.055198
0.064628
0.057193
0.066945
0.069464
0.079045
0.081417
0.090871

SCF
-231.6307342
-341.0120373
-270.9588626
-380.3452909
-346.1860902
-455.5706279
-330.9008433
-440.2809335
-323.902655
-433.270922
-436.2029292
-545.5680772
-420.275383
-529.6480771
-400.3998003
-509.7755186

Total ΔG° (H)
-231.5714142
-340.9429963
-270.8764286
-380.2526659
-346.0978112
-455.4726559
-330.8511303
-440.2215125
-323.847457
-433.206294
-436.1457362
-545.5011322
-420.205919
-529.5690321
-400.3183833
-509.6846476

0.077896
0.086966

-835.6893347
-945.0593439

-835.6114387
-944.9723779

0.055793
0.067554
0.065642
0.075277
0.091459
0.10012

-568.7884435
-678.1593088
-344.9942206
-454.3656925
-384.3281565
-493.7024455

-568.7326505
-678.0917548
-344.9285786
-454.2904155
-384.2366975
-493.6023255
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Table B2. Exchange Reaction Table
Exchange table

MeOPh
MePh
Ph
FPh
CNPh
NO2Ph
COOHPh
CONH2Ph
SO2NH2Ph
CF3Ph
CHO
acetyl

ΔGexchange (H)

ΔGexchange (Kcal/mol)

0.003262564
0.004655153
0
-0.001199917
-0.012745079
-0.016186177
-0.008469024
-0.005317811
-0.010642882
-0.012477806
-0.009745253
-0.005954126

2.047288273
2.921150404
0
-0.752958717
-7.997651778
-10.15697174
-5.314388781
-3.336974263
-6.678504241
-7.829935565
-6.115233965
-3.736267652

ΔGexchange /-1.36
(Kcal/mol)
-1.505359024
-2.147904709
0
0.553646115
5.880626308
7.468361576
3.90763881
2.453657546
4.910664883
5.757305563
4.496495562
2.747255627
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Table B3. Figure 2.3, and B1–B3 data tables
Figure 4 data

σp

ΔGexchange /-1.36
(Kcal/mol)

MeOPh
MePh
Ph
FPh
CNPh
NO2Ph
COOHPh
CONH2Ph
SO2NH2Ph
CF3Ph
CHO
acetyl

-0.27
-0.17
0
0.062
0.66
0.778
0.45
0.36
0.6
0.54
0.42
0.5

-1.505359024
-2.147904709
0
0.553646115
5.880626308
7.468361576
3.90763881
2.453657546
4.910664883
5.757305563
4.496495562
2.747255627
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Table B4. Figure B1 data
Figure B1 data

σP+

ΔGexchange /-1.36
(Kcal/mol)

MeOPh
MeOPh
MePh
Ph
FPh
CNPh
NO2Ph
COOHPh
CONH2Ph
SO2NH2Ph
CF3Ph
CHO
acetyl

-0.648
-0.648
-0.256
0
-0.247
0.674
0.74
0.472

-1.505359024
-2.147904709
0
0.553646115
5.880626308
7.468361576
3.90763881
2.453657546

0.582

4.496495562

0.567

-1.505359024
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Table B5. Figure B2 data
Figure B2 data

σp

MeOPh
MePh
Ph
FPh
CNPh
NO2Ph
COOHPh
CONH2Ph
SO2NH2Ph
CF3Ph
CHO
acetyl

-0.27
-0.17
0
0.062
0.66
0.778
0.45
0.36
0.6
0.54
0.42
0.5

∆Ar-N2+ Bond
length (Å)
0.00725
0.00676
0
0.0044
-0.0059
-0.00958
-0.0053
-0.00191
-0.00488
-0.00657
-0.00576
-0.00357
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Table B6. Figure B3 data
Figure B3
data
MeOPh
MePh
Ph
FPh
CNPh
NO2Ph
COOHPh
CONH2Ph
SO2NH2Ph
CF3Ph
CHO
acetyl

σp

Δ cm-1

-0.27
-0.17
0
0.062
0.66
0.778
0.45
0.36
0.6
0.54
0.42
0.5

10
14.0483
0
12.323
-5.4388
-7.2493
-5.7453
-1.6085
-3.2415
-4.622
-8.9973
-3.2252
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Input file example:
%chk=D:\Derek 2\CH3Phdiazonium20.chk
%nprocshared=8
%mem=1GB
# opt=tight freq=noraman ub3lyp/6-31+g(d)
scrf=(solvent=dichloromethane)
Title Card Required
1 1
C
C
C
C
C
C
H
H
H
H
N
N
C
H
H
H

2.46485803
3.60956637
4.87472960
4.99518451
3.85047573
2.58531251
1.49887803
3.51759643
5.96116503
3.94244572
6.07547261
6.96745478
1.32739080
1.11995660
1.49282498
0.49538028

-0.20846177
-0.85816272
-0.49876723
0.51032938
1.16002680
0.80063132
-0.48286655
-1.62862996
0.78473847
1.93049442
-1.18027181
-1.68653256
1.51458472
2.36948310
1.82772188
0.84260769

-0.44252761
0.03856847
-0.44528983
-1.41024402
-1.89134385
-1.40748555
-0.07308932
0.77533286
-1.77967775
-2.62810783
0.05935632
0.43423212
-1.93616648
-1.32705254
-2.94585784
-1.90291932

--Link1-%chk=D:\Derek 2\CH3Phdiazonium20.chk
%NProcShared=8
%mem=1GB
# ub3lyp/6-311++g(2d,p) scrf=(solvent=dichloromethane)
geom=allchk guess=read
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Figure B1. Hammet Plot of Calculated Log (KR/KH) Values vs σp+ Valuesa in CH2Cl2 Solvent
10

ΔGExchange = 6.3x + 1.19
R² = 0.84

8

CN

6

Log (KR/KH)

NO2
CF3

4
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COCH3
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F
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OCH3
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H

CH3

-4
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-0.1
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0.3

0.5

0.7

0.9

σP+
The σp+ values for sulfonamide, amide, and aldehyde para substituents were not available from
literature sources; consequently the corresponding data points are absent from Figure B1
a
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Figure B2. Difference in Bond Distancesa vs σp Values
0.010
0.008

∆Ar-N2+ Bond distance =-0.0155x + 0.003
R² = 0.91

OCH3 CH
3

0.006

F

∆Ar-N2+ Bond length (Å)

0.004
0.002
0.000
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-0.002
-0.004
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-0.006
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SO2NH2
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CF3

-0.008
NO2

-0.010
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Bond distance = H-Ar-N2+ - X-Ar-N2+ , X = substituent
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Figure B3. Difference in Bond Frequencya vs σp
18
CH3

13

F

∆ν = -20.084x + 6.2893
R² = 0.74

OCH3
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The 4-aminopyridine diazonium was not included in the Hammet plots since the pyridine ring is
not analogous to a para substituted phenyl system and no literature p constant exists.
Nonetheless, DFT calculations of the 4-pyridinediazonium cation resulted in a carbon diazonium
C-N bond length of 1.3917 Å and a vibrational frequency of 1127 cm-1. These results show that
4-pyridinediazonium cation has a longer bond length and smaller bond frequency than any of the
previously analyzed aryl compounds (Figures B2 and B3) supporting a C-N bond more
susceptible to homolytic bond cleavage. The pyridine core should then have a similar effect as
para EWGs on the phenyl system in regards to diazonium degradation and radical stability. Jones
et al. (1995) conducted ab initio studies on the thermal decomposition of pyridine and found the
bond dissociation energy (BDE) for the conversion of benzene to its radical was 1.5 kcal/mol
higher than pyridine, 109.3 kcal/mol vs 107.8 kcal/mol, respectively. A smaller BDE is associated
with a more stable radical indicating that the pyridyl radical is more stable when compared to the
phenyl radical. Both the strength of the diazonium bond and the stability of the free radical
would influence the RLS shown in Scheme 2.4.
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Appendix C: NMR spectra of aryl hydantoin target compounds, chapter 3
7-(4-fluoro-3-(trifluoromethyl)phenyl)-5,7-diazaspiro[3.4]octane-6,8-dione (5)

115
3-(4-fluoro-3-(trifluoromethyl)phenyl)-8-thia-1,3-diazaspiro[4.5]decane-2,4-dione 8,8-dioxide (6)

116
8-(ethylsulfonyl)-3-(4-fluoro-3-(trifluoromethyl)phenyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione
(7)

117
3-(4-fluoro-3-(trifluoromethyl)phenyl)-5,5-bis(fluoromethyl)imidazolidine-2,4-dione (8)

118
5-(difluoromethyl)-3-(4-fluoro-3-(trifluoromethyl)phenyl)-5-methylimidazolidine-2,4-dione (9)

119
3-(4-fluoro-3-(trifluoromethyl)phenyl)-5-methyl-5-(trifluoromethyl)imidazolidine-2,4-dione (10)

120
3-(4-fluoro-3-(trifluoromethyl)phenyl)-5-methyl-5-(2,2,2-trifluoroethyl)imidazolidine-2,4-dione
(11)

121
3-(4-fluoro-3-(trifluoromethyl)phenyl)-5,5-bis(methyl-d3)imidazolidine-2,4-dione (12)

122
3-(3,4-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (13)

123
3-(3-bromo-4-fluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (14)

124
3-(4-fluoro-3-(methylsulfonyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione (15)

125
3-(3-(1,1-difluoroethyl)-4-fluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (16)

126
3-(3-(1,1-difluoropropyl)-4-fluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (17)

127
3-(4-fluoro-3-(2,2,2-trifluoroethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione (18)

128
3-(4-fluoro-3-(trifluoromethoxy)phenyl)-5,5-dimethylimidazolidine-2,4-dione (19)

129
5,5-dimethyl-3-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)imidazolidine-2,4-dione (20)

130
5,5-dimethyl-3-(6-(trifluoromethyl)pyridin-2-yl)imidazolidine-2,4-dione (21)

131
3-(2,4-difluoro-3-(trifluoromethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione (22)

132
3-(3-chloro-4-fluoro-5-(trifluoromethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione (23)

133
2-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-5-fluoro-4-(trifluoromethyl)benzonitrile (24)

134
5,5-dimethyl-3-(3-(pentafluoro-l6-sulfaneyl)phenyl)imidazolidine-2,4-dione (25)

135
3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-5,5-dimethylimidazolidine-2,4-dione (26)

136
3-(3-(1,1-difluoroethyl)-4-fluorophenyl)-5,5-bis(methyl-d3)imidazolidine-2,4-dione (27)

137
3-(3-(1,1-difluoroethyl)-4-fluorophenyl)-5-methyl-5-(trifluoromethyl)imidazolidine-2,4-dione
(28)
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